VIICTR
Profiles
ORIT
Pediatrics RRO
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
HONG, DAVID SANGHYUN
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
DAVID SANGHYUN HONG
Title
Associate Professor
Institution
MD Anderson
Department
Investigational Cancer Therapeutics
Address
1400 Holcombe Blvd
Houston TX 77030-4008
vCard
Download vCard
Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can
login
to make corrections and additions.
Newest
|
Oldest
|
Most Cited
|
Most Discussed
|
Timeline
|
Field Summary
|
Plain Text
PMC Citations
indicate the number of times the publication was cited by articles in PubMed Central, and the
Altmetric
score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.)
Fields
are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication.
Translation
tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Carmagnani Pestana R, Moyers JT, Roszik J, Sen S,
Hong DS
,
Naing A
,
Herzog CE
,
Fu S
,
Piha-Paul SA
, Rodon J, Yap TA,
Karp DD
,
Tsimberidou AM
,
Pant S
,
Zarzour MA
,
Ratan R
,
Ravi V
, Benjamin RS,
Lazar AJ
, Wang WL, Daw N, Gill JB, Harrison DJ,
Lewis VO
,
Roland CL
,
Patel SR
, Livingston JA,
Somaiah N
,
Ludwig JA
,
Conley AP
, Hamerschlak N, Gorlick R,
Meric-Bernstam F
,
Subbiah V
. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res. 2023 05 01; 29(9):1708-1718.
PMID:
37058010
; PMCID:
PMC10150251
.
Citations:
Fields:
Neo
Neoplasms
Surana R, Gonzalez GN, Rogers J,
Hong DS
, Yap TA, Rodon J,
Naing A
,
Wolff RA
, Smaglo BG, Bernstam FM,
Subbiah V
,
Pant S
. Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials. J Gastrointest Cancer. 2023 Apr 29.
PMID:
37119430
.
Citations:
Fields:
Gas
Gastroenterology
Neo
Neoplasms
Dy GK, Govindan R, Velcheti V, Falchook GS, Italiano A, Wolf J, Sacher AG, Takahashi T, Ramalingam SS, Dooms C, Kim DW, Addeo A, Desai J, Schuler M, Tomasini P,
Hong DS
, Lito P, Tran Q, Jones S, Anderson A, Hindoyan A, Snyder W,
Skoulidis F
, Li BT. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol. 2023 Apr 25; JCO2202524.
PMID:
37098232
.
Citations:
Fields:
Neo
Neoplasms
Alhalabi O, Groisberg R, Zinner R, Hahn AW,
Naing A
, Zhang S,
Tsimberidou AM
, Rodon J,
Fu S
, Yap TA,
Hong DS
, Sun M, Jiang Y,
Pant S
,
Shah AY
, Zurita A,
Tannir NM
,
Vikram R
, Roszik J,
Meric-Bernstam F
,
Subbiah V
. Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol. 2023 Apr 18; 7(1):37.
PMID:
37072571
; PMCID:
PMC10113233
.
Citations:
Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, Delasos L, Hicks JK, Aldea M, Minuti G, Hines J, Aredo JV, Dennis MJ, Chakrabarti T, Scott SC, Bironzo P, Scheffler M, Christopoulos P, Stenzinger A, Riess JW, Kim SY, Goldberg SB, Li M, Wang Q, Qing Y, Ni Y, Do MT, Lee R, Ricciuti B, Alessi JV, Wang J, Resuli B, Landi L, Tseng SC, Nishino M, Digumarthy SR, Rinsurongkawong W, Rinsurongkawong V,
Vaporciyan AA
,
Blumenschein GR
, Zhang J, Owen DH, Blakely CM, Mountzios G, Shu CA, Bestvina CM, Garassino MC, Marrone KA, Gray JE, Patel SP, Cummings AL, Wakelee HA, Wolf J, Scagliotti GV, Cappuzzo F, Barlesi F, Patil PD, Drusbosky L,
Gibbons DL
,
Meric-Bernstam F
, Lee JJ,
Heymach JV
,
Hong DS
, Heist RS, Awad MM,
Skoulidis F
. Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC. Cancer Discov. 2023 Apr 17.
PMID:
37068173
.
Citations:
Fields:
Neo
Neoplasms
Nelson BE,
Saleem S
,
Damodaran S
,
Somaiah N
,
Piha-Paul S
, Moore JA, Yilmaz B, Ogbonna D,
Karp DD
, Dumbrava E,
Tsimberidou AM
,
Hong DS
, Rodon Ahnert J, Milton DR, Zheng X,
Booser DJ
,
Ibrahim NK
,
Conley AP
, Bhosale P,
Rojas Hernandez CM
,
Tripathy D
,
Naing A
,
Meric-Bernstam F
. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer. 2023 Apr 04.
PMID:
37016732
.
Citations:
Fields:
Neo
Neoplasms
Hallick J, Baird AM, Falchook G, Le X,
Hong D
, Viteri S, Raskin J, Reinmuth N, Vlassak S, Militaru M, Paik PK. Plain language summary of the development of tepotinib: a treatment for a subtype of non-small cell lung cancer?called MET exon 14 skipping. Future Oncol. 2023 Mar; 19(10):683-696.
PMID:
36999526
.
Citations:
Fields:
Neo
Neoplasms
Hong DS
, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Eganelisib, a First-in-Class PI3K-? Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 Mar 31.
PMID:
37000164
.
Citations:
Fields:
Neo
Neoplasms
He K,
Hong DS
, Tang C, Sezen D, Cox L, Maleki A, Bertolet G, Nguyen QN, Comeaux NI, Schuda L, Chen D,
Welsh JW
. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease. Radiother Oncol. 2023 Mar 13; 183:109618.
PMID:
36921766
.
Citations:
Fields:
Neo
Neoplasms
Rad
Radiotherapy
Hong D
, Shin D, Lee SH, Joh HS, Choi KH, Kim HK, Ha SJ, Park TK, Yang JH, Song YB, Hahn JY, Choi SH, Gwon HC, Lee JM. Prognostic Impact of Coronary Microvascular Dysfunction According to Different Patterns by Invasive Physiologic Indexes in Symptomatic Patients With Intermediate Coronary Stenosis. Circ Cardiovasc Interv. 2023 03; 16(3):e012621.
PMID:
36846961
.
Citations:
Fields:
Car
Cardiology
Vas
Vascular Diseases
Translation:
Humans
CT
Clinical Trials
He K, Berz D, Gadgeel SM, Iams WT, Bruno DS, Blakely CM, Spira AI, Patel MR, Waterhouse DM, Richards DA, Pham A, Jotte R,
Hong DS
, Garon EB, Traynor A, Olson P, Latven L, Yan X, Shazer R, Leal TA. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. J Thorac Oncol. 2023 Feb 24.
PMID:
36842467
.
Citations:
Fields:
Neo
Neoplasms
Pul
Pulmonary Medicine
Nelson BE, Roszik J,
Janku F
,
Hong DS
, Kato S,
Naing A
,
Piha-Paul S
,
Fu S
,
Tsimberidou A
,
Cabanillas M
,
Busaidy NL
,
Javle M
,
Byers LA
,
Heymach JV
,
Meric-Bernstam F
,
Subbiah V
. BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) study. NPJ Precis Oncol. 2023 Feb 18; 7(1):19.
PMID:
36801912
; PMCID:
PMC9938883
.
Citations:
Degner N, Scott ER,
Hong D
, Dalai SC, Blair L, Hollemon D, Chang E, Ho C, Ahmed AA, Eichenberger EM, Ruffin F, Franzone J, Sharma-Kuinkel B, Shah P, Wanda L, de Vries CR, Fowler VG. Microbial Cell-Free DNA Identifies the Causative Pathogen in Infective Endocarditis and Remains Detectable Longer Than Conventional Blood Culture in Patients with Prior Antibiotic Therapy. Clin Infect Dis. 2023 02 08; 76(3):e1492-e1500.
PMID:
35684984
; PMCID:
PMC10169441
.
Citations:
Fields:
Com
Communicable Diseases
Lee JM, Kim HK, Park KH, Choo EH, Kim CJ, Lee SH, Kim MC, Hong YJ, Ahn SG, Doh JH, Lee SY, Park SD, Lee HJ, Kang MG, Koh JS, Cho YK, Nam CW, Koo BK, Lee BK, Yun KH, Joh HS, Choi KH, Park TK, Yang JH, Song YB, Choi SH, Gwon HC, Hahn JY, FRAME-AMI Investigators,
Hong D
. Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial. Eur Heart J. 2023 02 07; 44(6):473-484.
PMID:
36540034
.
Citations:
1
Fields:
Car
Cardiology
Translation:
Humans
Lee JM, Joh HS, Choi KH,
Hong D
, Park TK, Yang JH, Song YB, Choi JH, Choi SH, Jeong JO, Lee JY, Choi YJ, Chae JK, Hur SH, Bae JW, Oh JH, Chun KJ, Kim HJ, Cho BR, Shin D, Lee SH, Hwang D, Lee HJ, Jang HJ, Kim HK, Ha SJ, Shin ES, Doh JH, Hahn JY, Gwon HC, SMART-REWARD Investigators. Safety and Efficacy of Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Second-Generation Drug-Eluting Stents in Real-World Practice. J Korean Med Sci. 2023 Feb 06; 38(5):e34.
PMID:
36747363
; PMCID:
PMC9902667
.
Citations:
Fields:
Med
Medicine (General)
Translation:
Humans
Chen CH, Chin RL, Hartley GP, Lea ST, Engel BJ, Hsieh CE, Prasad R, Roszik J,
Shingu T
,
Lizee GA
,
Heimberger AB
,
Millward SW
, Hu J,
Hong DS
,
Curran MA
. Novel Murine Glioblastoma Models That Reflect the Immunotherapy Resistance Profile of Human Disease. Neuro Oncol. 2023 Jan 27.
PMID:
36705543
.
Citations:
Fields:
Neo
Neoplasms
Neu
Neurology
Gounder MM, Bauer TM, Schwartz GK, Weise AM, LoRusso P, Kumar P, Tao B, Hong Y, Patel P, Lu Y, Lesegretain A, Tirunagaru VG, Xu F, Doebele RC,
Hong DS
. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas. J Clin Oncol. 2023 03 20; 41(9):1714-1724.
PMID:
36669146
; PMCID:
PMC10022862
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
CT
Clinical Trials
Yap TA,
Daver N
, Mahendra M, Zhang J, Kamiya-Matsuoka C,
Meric-Bernstam F
,
Kantarjian HM
, Ravandi F, Collins ME, Francesco MED, Dumbrava EE,
Fu S
, Gao S, Gay JP, Gera S, Han J,
Hong DS
,
Jabbour EJ
, Ju Z,
Karp DD
, Lodi A, Molina JR, Baran N,
Naing A
,
Ohanian M
,
Pant S
,
Pemmaraju N
,
Bose P
,
Piha-Paul SA
, Rodon J, Salguero C, Sasaki K, Singh AK,
Subbiah V
,
Tsimberidou AM
, Xu QA, Yilmaz M, Zhang Q, Li Y, Bristow CA, Bhattacharjee MB, Tiziani S, Heffernan TP, Vellano CP, Jones P,
Heijnen CJ
,
Kavelaars A
, Marszalek JR,
Konopleva M
. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials. Nat Med. 2023 01; 29(1):115-126.
PMID:
36658425
.
Citations:
8
Fields:
Med
Medicine (General)
Mol
Molecular Biology
Translation:
Animals
Cells
CT
Clinical Trials
Moyers JT, Pestana RC, Roszik J,
Hong DS
,
Naing A
,
Fu S
,
Piha-Paul S
, Yap TA,
Karp D
, Rodon J, Livingston A,
Zarzour MA
,
Ravi V
,
Patel S
, Benjamin RS,
Ludwig J
,
Herzog C
,
Ratan R
,
Somaiah N
,
Conley A
, Gorlick R,
Meric-Bernstam F
,
Subbiah V
. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res. 2023 01 17; 29(2):401-409.
PMID:
36288393
; PMCID:
PMC9843435
.
Citations:
Jordan TL, Klabunde M, Green T,
Hong DS
, Ross JL, Jo B, Reiss AL. Longitudinal investigation of cognition, social competence, and anxiety in children and adolescents with Turner syndrome. Horm Behav. 2023 03; 149:105300.
PMID:
36640638
; PMCID:
PMC9974892
.
Citations:
Fields:
Beh
Behavioral Sciences
End
Endocrinology
Translation:
Humans
Hong DS
, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM,
Araujo D
,
Blumenschein GR
,
Kebriaei P
, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand'Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO. Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2023 01; 29(1):104-114.
PMID:
36624315
; PMCID:
PMC9873554
.
Citations:
1
Fields:
Med
Medicine (General)
Mol
Molecular Biology
Translation:
Humans
CT
Clinical Trials
Son J, Lin HY,
Fu S
, Biter AB, Dumbrava EE,
Karp DD
,
Naing A
,
Pant S
,
Piha-Paul SA
, Rodon J,
Subbiah V
,
Tsimberidou AM
, Yap TA,
Frumovitz MM
,
Jazaeri AA
,
Ramirez PT
,
Westin SN
,
Yuan Y
,
Meric-Bernstam F
,
Hong DS
. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol. 2023 Feb; 6(1):10-18.
PMID:
36751659
; PMCID:
PMC9888522
.
Citations:
Coleman N, Marcelo KL, Hopkins JF, Khan NI, Du R, Hong L, Park E, Balsara B, Leoni M,
Pickering C
, Myers J,
Heymach J
, Albacker LA,
Hong D
, Gillison M, Le X. HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma. JCO Precis Oncol. 2023 01; 7:e2200211.
PMID:
36603172
; PMCID:
PMC9928766
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Strickler JH, Satake H, George TJ, Yaeger R, Hollebecque A, Garrido-Laguna I, Schuler M, Burns TF, Coveler AL, Falchook GS, Vincent M, Sunakawa Y, Dahan L, Bajor D, Rha SY, Lemech C, Juric D, Rehn M, Ngarmchamnanrith G, Jafarinasabian P, Tran Q,
Hong DS
. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. N Engl J Med. 2022 Dec 21.
PMID:
36546651
.
Citations:
5
Fields:
Med
Medicine (General)
Kollmannsberger C, Hurwitz H, Bazhenova L, Cho BC,
Hong D
, Park K, Reckamp KL, Sharma S, Der-Torossian H, Christensen JG, Faltaos D, Potvin D, Tassell V, Chao R, Shapiro GI. Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. Target Oncol. 2023 01; 18(1):105-118.
PMID:
36459255
.
Citations:
Westin SN
,
Fu S
,
Tsimberidou A
,
Piha-Paul S
, Akhmedzhanov F, Yilmaz B, McQuinn L, Brink AL, Gong J, Leung CH, Lin H,
Hong DS
,
Pant S
,
Carter B
,
Jazaeri A
, Gershenson D,
Sood AK
,
Coleman RL
, Shah J,
Meric-Bernstam F
,
Naing A
. Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer. Gynecol Oncol. 2023 01; 168:76-82.
PMID:
36423446
; PMCID:
PMC9797438
.
Citations:
Son J, Hsieh RC, Lin HY, Krause KJ,
Yuan Y
, Biter AB,
Welsh J
,
Curran MA
,
Hong DS
. Inhibition of the CD47-SIRPa axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol. 2022; 13:1027235.
PMID:
36439116
; PMCID:
PMC9691650
.
Citations:
Akhave NS, Biter AB,
Hong DS
. The Next Generation of KRAS Targeting: Reasons for Excitement and Concern. Mol Cancer Ther. 2022 11 03; 21(11):1645-1651.
PMID:
36282862
; PMCID:
PMC9633538
.
Citations:
Vo HH, Fu S,
Hong DS
,
Karp DD
,
Piha-Paul S
,
Subbiah V
,
Janku F
,
Naing A
, Yap TA, Rodon J,
Ajani JA
, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C,
Vining DJ
,
Berry DA
,
Meric-Bernstam F
,
Tsimberidou AM
. Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol. 2022 Oct 27; 6(1):78.
PMID:
36302890
; PMCID:
PMC9612600
.
Citations:
Camidge DR, Barlesi F, Goldman JW, Morgensztern D, Heist R, Vokes E, Spira A, Angevin E, Su WC,
Hong DS
, Strickler JH, Motwani M, Dunbar M, Parikh A, Noon E, Blot V, Wu J, Kelly K. Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 02 10; 41(5):1105-1115.
PMID:
36288547
; PMCID:
PMC9928626
.
Citations:
Rodrigues AJ, Medress ZA, Sayadi J, Bhambhvani H, Falkson SR, Jokhai R, Han SS,
Hong DS
. Predictors of spine metastases at initial presentation of pediatric brain tumor patients: a single-institution study. Childs Nerv Syst. 2023 03; 39(3):603-608.
PMID:
36266365
.
Citations:
Tan WK, Segal BD, Curtis MD, Baxi SS, Capra WB, Garrett-Mayer E,
Hobbs BP
,
Hong DS
, Hubbard RA, Zhu J, Sarkar S, Samant M. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations. Contemp Clin Trials Commun. 2022 Dec; 30:101000.
PMID:
36186544
; PMCID:
PMC9519429
.
Citations:
Nunes JC, Carroll MK, Mahaffey KW, Califf RM, Doraiswamy PM, Short S, Shah SH, Swope S, Williams D, Hernandez AF,
Hong DS
. General Anxiety Disorder-7 Questionnaire as a marker of low socioeconomic status and inequity. J Affect Disord. 2022 11 15; 317:287-297.
PMID:
36031002
.
Citations:
Mendoza TR
,
Hong DS
, Peterson CB, Stephen B, Dumbrava E, Pant S,
Tsimberidou AM
, Yap TA,
Sheshadri A
, Altan M,
George G
, Castillo L, Rodriguez E, Gong J,
Subbiah V
,
Janku F
,
Fu S
,
Piha-Paul SA
, Ahnert JR,
Karp DD
,
Cleeland C
,
Meric-Bernstam F
,
Naing A
. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367.
PMID:
35999229
; PMCID:
PMC9399082
.
Citations:
Kato S, Fujiwara Y,
Hong DS
. Targeting KRAS: Crossroads of Signaling and Immune Inhibition. J Immunother Precis Oncol. 2022 Aug; 5(3):68-78.
PMID:
36034582
; PMCID:
PMC9390702
.
Citations:
Hong DS
, Gopal AK, Shoushtari AN, Patel SP, He AR, Doi T, Ramalingam SS, Patnaik A, Sandhu S, Chen Y, Davis CB, Fisher TS, Huang B, Fly KD, Ribas A. Utomilumab in Patients With Immune Checkpoint Inhibitor-Refractory Melanoma and Non-Small-Cell Lung Cancer. Front Immunol. 2022; 13:897991.
PMID:
35983060
; PMCID:
PMC9379324
.
Citations:
Thein KZ, Biter AB, Banks KC, Duda AW, Saam J, Roszik J,
Janku F
,
Skoulidis F
,
Heymach JV
, Kopetz S,
Meric-Bernstam F
,
Hong DS
. Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer. JCO Precis Oncol. 2022 07; 6:e2100547.
PMID:
35862868
; PMCID:
PMC9365336
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Gouda MA, Huang HJ,
Piha-Paul SA
, Call SG,
Karp DD
,
Fu S
,
Naing A
,
Subbiah V
,
Pant S
, Dustin DJ,
Tsimberidou AM
,
Hong DS
, Rodon J,
Meric-Bernstam F
,
Janku F
. Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers. JCO Precis Oncol. 2022 07; 6:e2100512.
PMID:
35834760
; PMCID:
PMC9307306
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Eichenberger EM, de Vries CR, Ruffin F, Sharma-Kuinkel B, Park L,
Hong D
, Scott ER, Blair L, Degner N, Hollemon DH, Blauwkamp TA, Ho C, Seng H, Shah P, Wanda L, Fowler VG, Ahmed AA. Microbial Cell-Free DNA Identifies Etiology of Bloodstream Infections, Persists Longer Than Conventional Blood Cultures, and Its Duration of Detection Is Associated With Metastatic Infection in Patients With Staphylococcus aureus and Gram-Negative Bacteremia. Clin Infect Dis. 2022 06 10; 74(11):2020-2027.
PMID:
34460909
; PMCID:
PMC9187311
.
Citations:
3
Fields:
Com
Communicable Diseases
Translation:
Humans
Cells
Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J,
Hong DS
,
Fu S
, Yap TA, Murphy MB,
Piha-Paul S
,
Daver NG
, Rojas-Hernandez CM,
Naing A
. Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience. J Hematol. 2022 Jun; 11(3):113-120.
PMID:
35837373
; PMCID:
PMC9275440
.
Citations:
van Tilburg CM, Boni V, Capra M, Chisholm J, Chung HC, DuBois SG, Gallego-Melcon S, Gerber NU, Goto H, Grilley-Olson JE, Hansford JR,
Hong DS
, Italiano A, Kang HJ, Nysom K, Stefanowicz J, Tahara M, Ziegler DS, Gavrilovic IT, Norenberg R, Dima L, De La Cuesta E, Laetsch TW, Drilon A, Perreault S, Doz F, Geoerger B, H?jgaard M, ?ra I, Thorwarth A. Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors. Neuro Oncol. 2022 06 01; 24(6):997-1007.
PMID:
34850167
; PMCID:
PMC9159442
.
Citations:
7
Fields:
Neo
Neoplasms
Neu
Neurology
Translation:
Humans
CT
Clinical Trials
Yao S,
Meric-Bernstam F
,
Hong D
,
Janku F
,
Naing A
,
Piha-Paul SA
,
Tsimberidou AM
,
Karp D
,
Subbiah V
, Yap TA, Ahnert JR,
Pant S
, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y,
Fu S
. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci Rep. 2022 05 24; 12(1):8701.
PMID:
35610322
; PMCID:
PMC9130298
.
Citations:
Fields:
Sci
Science
Translation:
Humans
Ibarra Rovira J,
Thirumurthi S
,
Taggart M
, Yilmaz B, Lin H, Zhong LL, Ejezie CL, Akhmedzhanov FO, Zarifa A, Leung CH,
Hong DS
,
Vikram R
. Role of Abdominal and Pelvic CT Scans in Diagnosis of Patients with Immunotherapy-Induced Colitis. J Immunother Precis Oncol. 2022 May; 5(2):32-36.
PMID:
35664090
; PMCID:
PMC9153249
.
Citations:
Kim AJ,
Hong DS
,
George GC
. Dietary influences on symptomatic and non-symptomatic toxicities during cancer treatment: A narrative review. Cancer Treat Rev. 2022 Jul; 108:102408.
PMID:
35623220
.
Citations:
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Le X, Baik C, Bauman J, Gilbert J, Brose MS, Grilley-Olson JE, Patil T, McDermott R, Raez LE, Johnson JM, Shen L, Tahara M, Ho AL, Norenberg R, Dima L, Brega N, Drilon A,
Hong DS
. Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. Oncologist. 2022 May 10.
PMID:
35536733
.
Citations:
Fields:
Neo
Neoplasms
Hobbs BP
, Zabor EC, Kaizer AM,
Hong DS
, Pestana RC. Basket Trials: Review of Current Practice and Innovations for Future Trials. J Clin Oncol. 2022 10 20; 40(30):3520-3528.
PMID:
35537102
.
Citations:
Fields:
Neo
Neoplasms
Raghav KP
, Stephen B,
Karp DD
,
Piha-Paul SA
,
Hong DS
, Jain D, Chudy Onwugaje DO, Abonofal A, Willett AF,
Overman M
, Smaglo B, Huey RW,
Meric-Bernstam F
,
Varadhachary GR
,
Naing A
. Efficacy of pembrolizumab in patients with advanced cancer of unknown primary (CUP): a phase 2 non-randomized clinical trial. J Immunother Cancer. 2022 05; 10(5).
PMID:
35618285
; PMCID:
PMC9125753
.
Citations:
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Waguespack SG
, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N,
Hong DS
,
Cabanillas ME
, Leyvraz S. Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol. 2022 Apr 29; 186(6):631-643.
PMID:
35333737
; PMCID:
PMC9066591
.
Citations:
1
Fields:
End
Endocrinology
Translation:
Humans
Harding JJ, Garrido-Laguna I, Chen X, Basu C, Dowlati A, Forgie A, Hooper AT, Kamperschroer C, Max SI, Moreau A, Shannon M, Wong GY,
Hong DS
. A Phase 1 Dose-Escalation Study of PF-06671008, a Bispecific T-Cell-Engaging Therapy Targeting P-Cadherin in Patients With Advanced Solid Tumors. Front Immunol. 2022; 13:845417.
PMID:
35493516
; PMCID:
PMC9047766
.
Citations:
Fields:
All
Allergy and Immunology
Translation:
Humans
CT
Clinical Trials
Son J,
George GC
, Nardo M, Krause KJ,
Jazaeri AA
, Biter AB,
Hong DS
. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecol Oncol. 2022 06; 165(3):664-670.
PMID:
35400527
; PMCID:
PMC9133136
.
Citations:
Fields:
Gyn
Gynecology
Neo
Neoplasms
Translation:
Humans
Cells
Thein KZ,
Karp DD
,
Tsimberidou A
, Gong J, Sulovic S, Shah J,
Hong DS
,
Janku F
, McQuinn L, Stephen BA,
Colen R
,
Carter BW
, Yap TA,
Piha-Paul SA
,
Fu S
,
Meric-Bernstam F
,
Naing A
, Milton DR. Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 Apr; 40(2):463.
PMID:
34731355
; PMCID:
PMC8993707
.
Citations:
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Hong DS
, Butler MO, Pachynski RK, Sullivan R,
Kebriaei P
, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front Oncol. 2022; 12:818679.
PMID:
35372008
; PMCID:
PMC8972123
.
Citations:
1
DiPeri TP, Demirhan M,
Karp DD
,
Fu S
,
Hong DS
,
Subbiah V
, Lim J, Ballester LY,
Tayar JH
,
Suarez-Almazor ME
,
Javle M
,
Meric-Bernstam F
. Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. J Immunother Precis Oncol. 2022 Feb; 5(1):26-30.
PMID:
35663835
; PMCID:
PMC9138421
.
Citations:
Tan DSW, Sarantopoulos J, Carvajal RD, Kyi C, Esaki T, Prawira A, Akerley W, De Braud F, Hui R, Zhang T, Soo RA, Maur M, Weickhardt A, Lau A, Samant TS, Longmire T, Chowdhury NR, Sabatos-Peyton CA, Patel N, Ramesh R, Hu T, Carion A, Gusenleitner D, Yerramilli-Rao P, Askoxylakis V, Kwak EL,
Hong DS
, Sch?ffski P, Mart?n M, Ochoa-de-Olza M, Krauss J, Deschler-Baier B. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ? anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer. 2022 02; 10(2).
PMID:
35217575
; PMCID:
PMC8883259
.
Citations:
6
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G,
Hong DS
, Wang JS, Steidl U, Walensky LD, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M,
Meric-Bernstam F
. Correction: Phase I Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2022 Jan 15; 28(2):429.
PMID:
35045962
.
Citations:
Fields:
Neo
Neoplasms
Califf RM, Wong C, Doraiswamy PM,
Hong DS
, Miller DP, Mega JL, Baseline Study Group. Biological and clinical correlates of the patient health questionnaire-9: exploratory cross-sectional analyses of the baseline health study. BMJ Open. 2022 Jan 04; 12(1):e054741.
PMID:
34983769
; PMCID:
PMC8728408
.
Citations:
Fields:
Med
Medicine (General)
Translation:
Humans
Thein KZ,
Piha-Paul SA
,
Tsimberidou A
,
Karp DD
,
Janku F
,
Fu S
,
Subbiah V
,
Hong DS
, Yap TA, Shah J, McQuinn L, Gong J, Tran Y,
Carter BW
,
Colen R
,
Meric-Bernstam F
,
Naing A
, Milton DR. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol. 2021 Dec 29; 10(1):59.
PMID:
34965890
; PMCID:
PMC8715578
.
Citations:
Fakih MG, Kopetz S, Kuboki Y, Kim TW, Munster PN, Krauss JC, Falchook GS, Han SW, Heinemann V, Muro K, Strickler JH,
Hong DS
, Denlinger CS, Girotto G, Lee MA, Henary H, Tran Q, Park JK, Ngarmchamnanrith G, Prenen H, Price TJ. Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. Lancet Oncol. 2022 01; 23(1):115-124.
PMID:
34919824
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D,
Tsao A
,
Hong D
, Raymond V, Paik P, Zhang J,
Heymach JV
. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol. 2021; 5.
PMID:
34957368
; PMCID:
PMC8694524
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Rudzinski ER, Hechtman J, Roy-Chowdhuri S, Rudolph M, Lockwood CM, Silvertown J, Wierzbinska J, Shen K, Norenberg R, Nogai H,
Hong DS
, Drilon A, Laetsch TW. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib. Cancer Genet. 2022 01; 260-261:46-52.
PMID:
34929613
.
Citations:
Fields:
Gen
Genetics
Neo
Neoplasms
Translation:
Humans
Camidge DR, Goldman JW, Morgensztern D, Heist R, Vokes E, Angevin E,
Hong DS
, Rybkin II, Barve M, Bauer TM, Delmonte A, Dunbar M, Motwani M, Parikh A, Noon E, Wu J, Blot V, Kelly K, Barlesi F. A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. JTO Clin Res Rep. 2022 Jan; 3(1):100262.
PMID:
35005654
; PMCID:
PMC8717236
.
Citations:
Sargent RE, Vazquez E, Kang I, Lu J, Manchandia T, Sheth P, Terando A, Nelson ME, Carr A,
Hong DS
, Sener SF. Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center. Am J Surg. 2022 03; 223(3):539-542.
PMID:
34801227
.
Citations:
Fields:
Gen
General Surgery
Translation:
Humans
Fu S
, Piccioni DE, Liu H, Lukas RV, Kesari S, Aregawi D,
Hong DS
, Yamaguchi K, Whicher K, Zhang Y, Chen YL, Poola N, Eddy J, Blum D. A phase I study of the WT2725 dosing emulsion in patients with advanced malignancies. Sci Rep. 2021 11 16; 11(1):22355.
PMID:
34785698
; PMCID:
PMC8595891
.
Citations:
Fields:
Sci
Science
Translation:
Humans
CT
Clinical Trials
Butner JD, Martin GV, Wang Z,
Corradetti B
, Ferrari M, Esnaola N, Chung C,
Hong DS
,
Welsh JW
, Hasegawa N,
Mittendorf EA
,
Curley SA
, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W,
Koay EJ
, Cristini V. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Elife. 2021 11 09; 10.
PMID:
34749885
; PMCID:
PMC8629426
.
Citations:
Fields:
Bio
Biology
Translation:
Humans
Hong DS
, Rixe O, Chiu VK, Forde PM, Dragovich T, Lou Y, Nayak-Kapoor A, Leidner R, Atkins JN, Collaku A, Fox FE, Marshall MA, Olszanski AJ. Mogamulizumab in Combination with Nivolumab in a Phase I/II Study of Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 02 01; 28(3):479-488.
PMID:
34753777
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Greenbaum U, Dumbrava EI, Biter AB,
Haymaker CL
,
Hong DS
. Engineered T-cell Receptor T Cells for Cancer Immunotherapy. Cancer Immunol Res. 2021 11; 9(11):1252-1261.
PMID:
34728535
.
Citations:
Fields:
All
Allergy and Immunology
Neo
Neoplasms
Translation:
Humans
Saleh MN, Patel MR, Bauer TM, Goel S, Falchook GS, Shapiro GI, Chung KY, Infante JR, Conry RM, Rabinowits G,
Hong DS
, Wang JS, Steidl U, Naik G, Guerlavais V, Vukovic V, Annis DA, Aivado M,
Meric-Bernstam F
. Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53. Clin Cancer Res. 2021 10 01; 27(19):5236-5247.
PMID:
34301750
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
CT
Clinical Trials
Thein KZ,
Karp DD
,
Tsimberidou A
, Gong J, Sulovic S, Shah J,
Hong DS
,
Janku F
, McQuinn L, Stephen BA,
Colen R
,
Carter BW
, Yap TA,
Piha-Paul SA
,
Fu S
,
Meric-Bernstam F
,
Naing A
, Milton DR. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. 2022 04; 40(2):290-299.
PMID:
34562230
; PMCID:
PMC8993773
.
Citations:
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Moore KN,
Hong DS
, Patel MR,
Pant S
, Ulahannan SV, Jones S,
Meric-Bernstam F
, Wang JS, Aljumaily R, Hamilton EP, Wittchen ES, Wang X, Lin AB, Bendell JC. A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. Target Oncol. 2021 09; 16(5):569-589.
PMID:
34559360
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hart J, Summer A, Yadav KN, Peace S,
Hong D
, Konu M, Clapp JT. Content and Communication of Inpatient Family Visitation Policies During the COVID-19 Pandemic: Sequential Mixed Methods Study. J Med Internet Res. 2021 09 24; 23(9):e28897.
PMID:
34406968
; PMCID:
PMC8477908
.
Citations:
Fields:
Med
Medical Informatics
Translation:
Humans
Cells
PH
Public Health
Rolfo C, Drilon A,
Hong D
, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types. Br J Cancer. 2022 02; 126(3):514-520.
PMID:
34480094
; PMCID:
PMC8811064
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
Kato S, Adashek JJ,
Subbiah V
,
Fu S
, Sun M, Nguyen L, Brown EJ, Yap TA,
Karp DD
,
Piha-Paul SA
,
Hong DS
. A phase i study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs. 2022 02; 40(1):99-105.
PMID:
34468905
.
Citations:
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Camidge DR, Morgensztern D, Heist RS, Barve M, Vokes E, Goldman JW,
Hong DS
, Bauer TM, Strickler JH, Angevin E, Motwani M, Parikh A, Sun Z, Bach BA, Wu J, Komarnitsky PB, Kelly K. Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. Clin Cancer Res. 2021 11 01; 27(21):5781-5792.
PMID:
34426443
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Mansfield AS,
Hong DS
, Hann CL, Farago AF, Beltran H, Waqar SN, Hendifar AE, Anthony LB, Taylor MH, Bryce AH, Tagawa ST, Lewis K, Niu J, Chung CH, Cleary JM, Rossi M, Ludwig C, Valenzuela R, Luo Y, Aggarwal R. A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. NPJ Precis Oncol. 2021 Aug 05; 5(1):74.
PMID:
34354225
; PMCID:
PMC8342450
.
Citations:
4
Zhu L,
Hobbs B
, Roszik J, Holla V,
Hong DS
. Investigating the natural history and prognostic nature of NTRK gene fusions in solid tumors. Invest New Drugs. 2022 02; 40(1):157-162.
PMID:
34341905
.
Citations:
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Alhalabi O, Hahn AW, Msaouel P,
Meric-Bernstam F
, Wilson N,
Naing A
,
Piha-Paul S
,
Janku F
,
Pant S
, Yap TA,
Hong DS
,
Fu S
,
Karp D
, Beltran K, Campbell E, Le H, Campbell MT, Shah A,
Tannir NM
,
Siefker-Radtke A
,
Gao J
, Roszik J,
Subbiah V
. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer. 2022 02; 20(1):e16-e24.
PMID:
34362693
.
Citations:
Fields:
Neo
Neoplasms
Uro
Urology
Translation:
Humans
Patel RR, He K, Barsoumian HB,
Chang JY
, Tang C, Verma V, Comeaux N,
Chun SG
, Gandhi S,
Truong MT
,
Erasmus JJ
,
Hong DS
, Lee PP, Ning MS, Nguyen QN,
Heymach JV
, Altan M,
Blumenschein G
,
Fossella FV
, Sezen D, Chen D,
Carter BW
,
Davies MA
,
Glitza IC
,
Diab A
,
Ferrarotto R
,
Cabanillas ME
,
Yuan Y
, Shah SJ, Parra ER, Sun B,
Cortez MA
,
Welsh JW
. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol. 2021 09; 162:60-67.
PMID:
34237343
.
Citations:
6
Fields:
Neo
Neoplasms
Rad
Radiotherapy
Translation:
Humans
CT
Clinical Trials
Cawkwell PB,
Hong DS
, Leikauf JE. Neurodevelopmental Effects of Cannabis Use in Adolescents and Emerging Adults with ADHD: A Systematic Review. Harv Rev Psychiatry. 2021 Jul-Aug 01; 29(4):251-261.
PMID:
34138796
; PMCID:
PMC9129887
.
Citations:
Fields:
Psy
Psychiatry
Translation:
Humans
Animals
Hart JL,
Hong D
, Summer A, Schnoll RA. Stakeholders' Views on Reducing Psychological Distress in Chronic Obstructive Pulmonary Disease. J Pain Symptom Manage. 2022 01; 63(1):e21-e28.
PMID:
34216748
; PMCID:
PMC8720110
.
Citations:
Fields:
Pal
Palliative Care
Psy
Psychophysiology
The
Therapeutics
Translation:
Humans
Kim ST
,
Tayar J
,
Fu S
, Ke D, Norry E, Sun A, Miller J,
Hong DS
. Newly developed pseudogout arthritis after therapy with MAGE-A4 directed TCR T cells responded to treatment with tocilizumab. J Immunother Cancer. 2021 07; 9(7).
PMID:
34233963
; PMCID:
PMC8264871
.
Citations:
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Kurzrock R, Lin CC, Wu TC,
Hobbs BP
,
Hong DS
, Pestana RC. Moving Beyond 3+3: The Future of Clinical Trial Design. Am Soc Clin Oncol Educ Book. 2021 Jun; 41:e133-e144.
PMID:
34061563
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Piha-Paul SA
, Dumbrava EE, Nair BC, Xiong W, Xu L, Mostorino R,
Subbiah V
,
Tannir N
,
Fu S
,
Naing A
,
Janku F
,
Karp DD
,
Patel S
, Daw NC,
Hong D
,
Meric-Bernstam F
, Zinner R. A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. Onco Targets Ther. 2021; 14:3037-3049.
PMID:
33994796
; PMCID:
PMC8114359
.
Citations:
2
Translation:
CT
Clinical Trials
Foland-Ross LC, Gil M, Shrestha SB, Chromik LC,
Hong D
, Reiss AL. Cortical gray matter structure in boys with Klinefelter syndrome. Psychiatry Res Neuroimaging. 2021 07 30; 313:111299.
PMID:
34038819
; PMCID:
PMC8321133
.
Citations:
Fields:
Dia
Diagnostic Imaging
Neu
Neurology
Psy
Psychiatry
Translation:
Humans
Xiong W, Friese-Hamim M, Johne A, Stroh C, Klevesath M, Falchook GS,
Hong DS
, Girard P, El Bawab S. Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose. CPT Pharmacometrics Syst Pharmacol. 2021 05; 10(5):428-440.
PMID:
33818908
; PMCID:
PMC8129711
.
Citations:
3
Fields:
Pha
Pharmacology
Translation:
Humans
Animals
Laetsch TW,
Hong DS
. Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion Cancer. Clin Cancer Res. 2021 09 15; 27(18):4974-4982.
PMID:
33893159
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Huey RW,
George GC
, Phillips P, White R,
Fu S
,
Janku F
,
Karp DD
,
Naing A
,
Piha-Paul S
,
Subbiah V
,
Tsimberidou AM
,
Pant S
, Yap TA, Rodon J,
Meric-Bernstam F
,
Shih YT
,
Hong DS
. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596.
PMID:
33783054
; PMCID:
PMC8265355
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Al-Zubidi N,
Gombos DS
,
Hong DS
,
Subbiah V
,
Fu S
, Ahnert JR,
Piha-Paul SA
,
Tsimberidou AM
,
Karp DD
, Bernstam FM,
Naing A
. Overview of Ocular Side Effects of Selinexor. Oncologist. 2021 07; 26(7):619-623.
PMID:
33728727
; PMCID:
PMC8265354
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Henry JT, Coker O, Chowdhury S, Shen JP,
Morris VK
, Dasari A,
Raghav K
, Nusrat M,
Kee B
, Parseghian C,
Pant S
, Jeyakumar N, Zhu L, Nishioka Y,
Fogelman D
,
Wolff RA
,
Hong D
,
Overman MJ
,
Vauthey J
, Kopetz S, Johnson B. Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer. JCO Precis Oncol. 2021; 5.
PMID:
34250391
; PMCID:
PMC8232253
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
Akhave NS, Biter AB,
Hong DS
. Mechanisms of Resistance to KRASG12C-Targeted Therapy. Cancer Discov. 2021 06; 11(6):1345-1352.
PMID:
33820777
; PMCID:
PMC8178176
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
Kummar S, Berlin J, Mascarenhas L, van Tilburg CM, Lassen UN, Schilder RJ, Turpin B, Nanda S, Keating K, Childs BH, Chirila C, Laetsch TW, Hyman DM, Drilon A,
Hong DS
, Geoerger B. Quality of Life in Adult and Pediatric Patients with Tropomyosin Receptor Kinase Fusion Cancer Receiving Larotrectinib. Curr Probl Cancer. 2021 12; 45(6):100734.
PMID:
33865615
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hegde A, Jayaprakash P, Couillault CA,
Piha-Paul S
,
Karp D
, Rodon J,
Pant S
,
Fu S
, Dumbrava EE, Yap TA,
Subbiah V
, Bhosale P,
Coarfa C
, Higgins JP, Williams ET, Wilson TF, Lim J,
Meric-Bernstam F
, Sumner E, Zain H, Nguyen D, Nguyen LM, Rajapakshe K,
Curran MA
,
Hong DS
. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clin Cancer Res. 2021 06 01; 27(11):3050-3060.
PMID:
33771853
; PMCID:
PMC8172466
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Tsimberidou AM
,
Hong DS
,
Fu S
,
Karp DD
,
Piha-Paul S
,
Kies MS
,
Ravi V
,
Subbiah V
, Patel SM, Tu SM,
Janku F
,
Heymach J
, Johnson A, Cartwright C, Zhao L, Zhang J,
Berry DA
,
Vining DJ
,
Futreal A
, Miller VA,
Meric-Bernstam F
. Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. NPJ Precis Oncol. 2021 Mar 19; 5(1):21.
PMID:
33742104
; PMCID:
PMC7979841
.
Citations:
2
Kim AJ,
Hong DS
,
George GC
. Diet-related interventions for cancer-associated cachexia. J Cancer Res Clin Oncol. 2021 May; 147(5):1443-1450.
PMID:
33718995
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Hajjar J
,
Mendoza T
, Zhang L, Fu S,
Piha-Paul SA
,
Hong DS
,
Janku F
,
Karp DD
, Ballhausen A, Gong J, Zarifa A, Peterson CB,
Meric-Bernstam F
, Jenq R,
Naing A
. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021 03 12; 11(1):5847.
PMID:
33712647
; PMCID:
PMC7954807
.
Citations:
7
Fields:
Sci
Science
Translation:
Humans
Cells
Yao S,
Janku F
,
Subbiah V
, Stewart J,
Patel SP
,
Kaseb A
,
Westin SN
,
Naing A
,
Tsimberidou AM
,
Hong D
,
Piha-Paul SA
, Shi N, Johnston A, Bomalaski J,
Fu S
. Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539.
PMID:
33674736
; PMCID:
PMC8076217
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Cleary B, Hay JA, Blumenstiel B, Harden M, Cipicchio M, Bezney J, Simonton B,
Hong D
, Senghore M, Sesay AK, Gabriel S, Regev A, Mina MJ. Using viral load and epidemic dynamics to optimize pooled testing in resource-constrained settings. Sci Transl Med. 2021 04 14; 13(589).
PMID:
33619080
; PMCID:
PMC8099195
.
Citations:
19
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Cells
PH
Public Health
Osarogiagbon RU, Vega DM, Fashoyin-Aje L, Wedam S, Ison G, Atienza S, De Porre P, Biswas T, Holloway JN,
Hong DS
, Wempe MM, Schilsky RL, Kim ES, Wade JL. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group. Clin Cancer Res. 2021 05 01; 27(9):2408-2415.
PMID:
33563637
; PMCID:
PMC8170959
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Moore KN, Bendell JC,
Karp DD
, Wang JS, Ulahannan SV, Jones S, Wu W, Donoho GP,
Ding Y
, Capen A, Wang X, Bence Lin A, Patel MR. Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. Clin Cancer Res. 2021 04 01; 27(7):1864-1874.
PMID:
33495309
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
CT
Clinical Trials
Butner JD, Wang Z, Elganainy D, Al Feghali KA, Plodinec M,
Calin GA
, Dogra P, Nizzero S, Martin GV,
Tawbi HA
, Chung C,
Koay EJ
,
Welsh JW
,
Hong DS
, Cristini V, Ruiz-Ram?rez J. A mathematical model for the quantification of a patient's sensitivity to checkpoint inhibitors and long-term tumour burden. Nat Biomed Eng. 2021 04; 5(4):297-308.
PMID:
33398132
; PMCID:
PMC8669771
.
Citations:
8
Fields:
Bio
Biomedical Engineering
Translation:
Humans
Kopetz S, Guthrie KA,
Morris VK
, Lenz HJ, Magliocco AM,
Maru D
, Yan Y, Lanman R, Manyam G,
Hong DS
, Sorokin A, Atreya CE, Diaz LA, Allegra C,
Raghav KP
, Wang SE, Lieu CH, McDonough SL, Philip PA, Hochster HS. Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406). J Clin Oncol. 2021 02 01; 39(4):285-294.
PMID:
33356422
; PMCID:
PMC8462593
.
Citations:
33
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY,
Meric-Bernstam F
,
Naing A
,
Piha-Paul S
, Filip J,
Pant S
, Yap TA,
Hong DS
,
Fu S
,
Karp D
, Campbell E, Le H, Campbell MT,
Shah AY
,
Tannir NM
,
Siefker-Radtke AO
,
Gao J
, Roszik J,
Subbiah V
. Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. Mol Cancer Res. 2021 03; 19(3):395-402.
PMID:
33323389
.
Citations:
1
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Neo
Neoplasms
Translation:
Humans
Hong DS
, Boike T, Dawes S, Klash SJ, Kudner R, Okoye C, Rosu-Bubulac M, Watanabe Y, Wright JL, Jennelle RL. Accreditation Program for Excellence (APEx): A Catalyst for Quality Improvement. Pract Radiat Oncol. 2021 Mar-Apr; 11(2):101-107.
PMID:
33279669
.
Citations:
Fields:
Neo
Neoplasms
Rad
Radiotherapy
Translation:
Humans
Italiano A, Nanda S, Briggs A, Lassen U, Vassal G, Kummar S, van Tilburg CM,
Hong DS
, Laetsch TW, Keating K, Reeves JA, Fellous M, Childs BH, Drilon A, Hyman DM, Garcia-Foncillas J. Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis. Cancers (Basel). 2020 Nov 04; 12(11).
PMID:
33158040
; PMCID:
PMC7692104
.
Citations:
6
Thein KZ, Biter AB,
Hong DS
. Therapeutics Targeting Mutant KRAS. Annu Rev Med. 2021 01 27; 72:349-364.
PMID:
33138715
.
Citations:
10
Fields:
Med
Medicine (General)
Translation:
Humans
Hahn AW, Alhalabi O, Msaouel P,
Meric-Bernstam F
,
Naing A
,
Jonasch E
,
Piha-Paul S
,
Hong D
,
Pant S
, Yap T, Campbell E, Le H,
Tannir NM
, Roszik J,
Subbiah V
. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open. 2020 11; 5(6):e001073.
PMID:
33229506
; PMCID:
PMC7684827
.
Citations:
Translation:
Humans
CT
Clinical Trials
Janku F
, Sakamuri D, Kato S, Huang HJ, Call SG,
Naing A
, Holley VR,
Patel SP
,
Amaria RN
, Falchook GS,
Piha-Paul SA
, Zinner RG,
Tsimberidou AM
,
Hong DS
,
Meric-Bernstam F
. Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. Cancer. 2021 02 01; 127(3):391-402.
PMID:
33119140
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Ballhausen A, Wheler JJ,
Karp DD
,
Piha-Paul SA
,
Fu S
,
Pant S
,
Tsimberidou AM
,
Hong DS
,
Subbiah V
, Holley VR, Huang HJ,
Brewster AM
,
Koenig KB
,
Ibrahim NK
,
Meric-Bernstam F
,
Janku F
. Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. Clin Cancer Res. 2021 03 01; 27(5):1247-1255.
PMID:
33115815
; PMCID:
PMC9011198
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Janku F
, Park H, Call SG, Madwani K,
Oki Y
,
Subbiah V
,
Hong DS
,
Naing A
, Velez-Bravo VM, Barnes TG,
Hagemeister FB
, Falchook GS,
Karp DD
, Wheler JJ,
Piha-Paul SA
, Garrido-Laguna I,
Shpall EJ
,
Fayad LE
,
Neelapu SS
,
Meric-Bernstam F
, Kurzrock R,
Fanale MA
. Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. Clin Cancer Res. 2020 11 01; 26(21):5579-5587.
PMID:
33055173
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Janku F
, Zhang HH, Pezeshki A, Goel S,
Murthy R
, Wang-Gillam A, Shepard DR, Helgason T, Masters T,
Hong DS
,
Piha-Paul SA
,
Karp DD
, Klang M,
Huang SY
, Sakamuri D, Raina A, Torrisi J, Solomon SB, Weissfeld A, Trevino E, DeCrescenzo G, Collins A, Miller M, Salstrom JL, Korn RL, Zhang L, Saha S, Leontovich AA, Tung D, Kreider B, Varterasian M, Khazaie K, Gounder MM. Intratumoral Injection of Clostridium novyi-NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. Clin Cancer Res. 2021 01 01; 27(1):96-106.
PMID:
33046513
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Mendoza T
,
Sheshadri A
, Altan M, Hess K,
George G
, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J,
Fu S
,
Piha-Paul SA
,
Pant S
, Dumbrava E, Yap TA,
Janku F
,
Tsimberidou AM
,
Subbiah V
,
Karp DD
, Zarifa A, McQuinn LM,
Cleeland C
,
Hong DS
,
Naing A
. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2).
PMID:
33097611
; PMCID:
PMC7590372
.
Citations:
3
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K,
Cabanillas M
,
Hu MI
,
Busaidy NL
,
Sherman SI
,
Dadu R
,
Grubbs EG
, Ali SM, Lee J, Elamin YY,
Simon GR
,
Blumenschein GR
,
Papadimitrakopoulou VA
,
Hong D
,
Meric-Bernstam F
,
Heymach J
,
Subbiah V
. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799.
PMID:
33097651
; PMCID:
PMC7590373
.
Citations:
10
Translation:
Humans
CT
Clinical Trials
Barsoumian HB, Ramapriyan R, Younes AI, Caetano MS, Menon H, Comeaux NI, Cushman TR, Schoenhals JE, Cadena AP, Reilly TP, Chen D, Masrorpour F, Li A,
Hong DS
,
Diab A
, Nguyen QN,
Glitza I
,
Ferrarotto R
,
Chun SG
,
Cortez MA
,
Welsh J
. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
PMID:
33106386
; PMCID:
PMC7592253
.
Citations:
24
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Animals
Siu L, Brody J, Gupta S, Jimeno A, Munster P, Grilley-Olson J, Rook AH, Hollebecque A, Wong RKS,
Welsh JW
, Wu Y, Morehouse C, Hamid O, Walcott F, Cooper ZA, Kumar R,
Hong DS
, Marabelle A, Fert? C. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2).
PMID:
33037117
; PMCID:
PMC7549442
.
Citations:
10
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Animals
Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris NRM, Bashir S, Drew Y,
Hong DS
,
Meric-Bernstam F
, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors. Cancer Discov. 2021 01; 11(1):80-91.
PMID:
32988960
; PMCID:
PMC9554790
.
Citations:
34
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, Falchook GS, Price TJ, Sacher A, Denlinger CS, Bang YJ, Dy GK, Krauss JC, Kuboki Y, Kuo JC, Coveler AL, Park K, Kim TW, Barlesi F, Munster PN, Ramalingam SS, Burns TF,
Meric-Bernstam F
, Henary H, Ngang J, Ngarmchamnanrith G, Kim J, Houk BE, Canon J, Lipford JR, Friberg G, Lito P, Govindan R, Li BT. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N Engl J Med. 2020 09 24; 383(13):1207-1217.
PMID:
32955176
; PMCID:
PMC7571518
.
Citations:
272
Fields:
Med
Medicine (General)
Translation:
Humans
CT
Clinical Trials
Jaiswal AR, Liu AJ, Pudakalakatti S, Dutta P, Jayaprakash P, Bartkowiak T, Ager CR, Wang ZQ, Reuben A, Cooper ZA,
Ivan C
, Ju Z, Nwajei F, Wang J,
Davies MA
, Davis RE,
Wargo JA
,
Bhattacharya PK
,
Hong DS
,
Curran MA
. Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype. Cancer Immunol Res. 2020 11; 8(11):1365-1380.
PMID:
32917656
; PMCID:
PMC7642111
.
Citations:
9
Fields:
All
Allergy and Immunology
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Atkins JT,
George GC
, Hess K, Marcelo-Lewis KL, Yuan Y,
Borthakur G
, Khozin S, LoRusso P,
Hong DS
. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. Br J Cancer. 2020 11; 123(10):1496-1501.
PMID:
32868897
; PMCID:
PMC7652903
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Subbiah V
, Erwin W,
Mawlawi O
, McCoy A, Wages D, Wheeler C,
Gonzalez-Lepera C
, Liu H,
Macapinlac H
,
Meric-Bernstam F
,
Hong DS
,
Pant S
, Le D,
Santos E
, Gonzalez J, Roszik J, Suzuki T, Subach RA, Madden T, Johansen M, Nomura F, Satoh H, Matsuura T, Kajita M, Nakamura E, Funase Y, Matsushima S,
Ravizzini G
. Phase I Study of P-cadherin-targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. Clin Cancer Res. 2020 11 15; 26(22):5830-5842.
PMID:
32816889
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Choi KH, Yang JH,
Hong D
, Park TK, Lee JM, Song YB, Hahn JY, Choi SH, Choi JH, Chung SR, Cho YH, Jeong DS, Sung K, Kim WS, Lee YT, Gwon HC. Optimal Timing of Venoarterial-Extracorporeal Membrane Oxygenation in Acute Myocardial Infarction Patients Suffering From Refractory Cardiogenic Shock. Circ J. 2020 08 25; 84(9):1502-1510.
PMID:
32684541
.
Citations:
6
Fields:
Car
Cardiology
Vas
Vascular Diseases
Translation:
Humans
Greenbaum U, Yalniz FF, Srour SA, Rezvani K, Singh H,
Olson A
,
Blumenschein G
,
Hong DS
,
Shpall EJ
,
Kebriaei P
. Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors? Biol Blood Marrow Transplant. 2020 10; 26(10):1759-1769.
PMID:
32623078
.
Citations:
4
Fields:
Hem
Hematology
Tra
Transplantation
Translation:
Humans
Cells
Sheth RA
,
Murthy R
,
Hong DS
, Patel S,
Overman MJ
,
Diab A
,
Hwu P
,
Tam A
. Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. JAMA Netw Open. 2020 07 01; 3(7):e207911.
PMID:
32725245
.
Citations:
7
Fields:
Med
Medicine (General)
Translation:
Humans
Cells
Zamarin D, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall MA,
Hong DS
. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clin Cancer Res. 2020 09 01; 26(17):4531-4541.
PMID:
32586937
; PMCID:
PMC8375360
.
Citations:
17
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Pestana RC, Sen S,
Hobbs BP
,
Hong DS
. Histology-agnostic drug development - considering issues beyond the tissue. Nat Rev Clin Oncol. 2020 09; 17(9):555-568.
PMID:
32528101
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Parikh A, Shapiro GI,
Naing A
,
Meric-Bernstam F
, Reyderman L, Binder TA, Ren M, Liu M, Dayal S, Siu AY, Sachdev P, Xu L, Bhagawati-Prasad V, Tchakov I, Ooi CE, Bao X, Varga A, Ataman ?, Marabelle A. First-in-human phase I study of immunomodulatory E7046, an antagonist of PGE2-receptor E-type 4 (EP4), in patients with advanced cancers. J Immunother Cancer. 2020 06; 8(1).
PMID:
32554609
; PMCID:
PMC7304851
.
Citations:
13
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Butner JD, Elganainy D, Wang CX, Wang Z, Chen SH, Esnaola NF, Pasqualini R, Arap W,
Hong DS
,
Welsh J
,
Koay EJ
, Cristini V. Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy. Sci Adv. 2020 05; 6(18):eaay6298.
PMID:
32426472
; PMCID:
PMC7190324
.
Citations:
9
Fields:
Sci
Science
Translation:
Humans
Subbiah V
, Dumbrava EI, Jiang Y, Thein KZ,
Naing A
,
Hong DS
,
Fu S
,
Piha-Paul SA
,
Tsimberidou AM
,
Janku F
,
Meric-Bernstam F
, Kurzrock R, Falchook G. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. Exp Hematol Oncol. 2020; 9:7.
PMID:
32337094
; PMCID:
PMC7171918
.
Citations:
5
Hong DS
, Kang YK, Borad M, Sachdev J, Ejadi S, Lim HY, Brenner AJ, Park K, Lee JL, Kim TY, Shin S, Becerra CR, Falchook G, Stoudemire J, Martin D, Kelnar K, Peltier H, Bonato V, Bader AG, Smith S, Kim S, O'Neill V, Beg MS. Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. Br J Cancer. 2020 05; 122(11):1630-1637.
PMID:
32238921
; PMCID:
PMC7251107
.
Citations:
144
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Groisberg R, Roszik J,
Conley AP
,
Lazar AJ
, Portal DE,
Hong DS
,
Naing A
,
Herzog CE
,
Somaiah N
,
Zarzour MA
,
Patel S
, Brown RE,
Subbiah V
. Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. Mol Cancer Ther. 2020 05; 19(5):1165-1172.
PMID:
32127467
; PMCID:
PMC8386165
.
Citations:
4
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Naing A
,
Meric-Bernstam F
, Stephen B,
Karp DD
,
Hajjar J
, Rodon Ahnert J,
Piha-Paul SA
,
Colen RR
,
Jimenez C
,
Raghav KP
,
Ferrarotto R
, Tu SM, Campbell M, Wang L, Sabir SH,
Tapia C
,
Bernatchez C
,
Frumovitz M
,
Tannir N
,
Ravi V
, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S,
Subbiah V
,
Hong DS
,
Pant S
, Yap TA,
Tsimberidou AM
, Dumbrava EEI,
Janku F
,
Fu S
, Simon RM,
Hess KR
,
Varadhachary GR
,
Habra MA
. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 03; 8(1).
PMID:
32188704
; PMCID:
PMC7078933
.
Citations:
32
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Kairemo K,
Santos EB
,
Macapinlac HA
,
Patel S
,
Conley AP
,
Hong DS
, Subbiah AV. Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (18F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. Diagnostics (Basel). 2020 Feb 25; 10(3).
PMID:
32106426
; PMCID:
PMC7151088
.
Citations:
1
Hong DS
, DuBois SG, Kummar S, Farago AF, Albert CM, Rohrberg KS, van Tilburg CM, Nagasubramanian R, Berlin JD, Federman N, Mascarenhas L, Dowlati A, Pappo AS, Bielack S, McDermott R, Patel JD, Schilder RJ, Tahara M, Pfister SM, Witt O, Ladanyi M, Rudzinski ER, Nanda S, Childs BH, Laetsch TW, Hyman DM, Drilon A, Geoerger B, Doz F. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020 04; 21(4):531-540.
PMID:
32105622
; PMCID:
PMC7497841
.
Citations:
149
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Wang Y,
Janku F
,
Piha-Paul S
, Hess K,
Broaddus R
, Liu L, Shi N,
Overman M
, Kopetz S,
Subbiah V
,
Naing A
,
Hong D
,
Tsimberidou AM
,
Karp D
,
Yao J
,
Fu S
. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Sci Rep. 2020 02 20; 10(1):3080.
PMID:
32080210
; PMCID:
PMC7033174
.
Citations:
2
Fields:
Sci
Science
Translation:
Humans
CT
Clinical Trials
Turner JD, Marriott AE,
Hong D
, O' Neill P, Ward SA, Taylor MJ. Novel anti-Wolbachia drugs, a new approach in the treatment and prevention of veterinary filariasis? Vet Parasitol. 2020 Mar; 279:109057.
PMID:
32126342
.
Citations:
2
Fields:
Par
Parasitology
Vet
Veterinary Medicine
Translation:
Animals
Cells
Kato S, Okamura R, Sicklick JK, Daniels GA,
Hong DS
, Goodman A, Weihe E, Lee S, Khalid N, Collier R, Mareboina M, Riviere P, Whitchurch TJ, Fanta PT, Lippman SM, Kurzrock R. Prognostic implications of RAS alterations in diverse malignancies and impact of targeted therapies. Int J Cancer. 2020 06 15; 146(12):3450-3460.
PMID:
31782524
; PMCID:
PMC10200262
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Bang YJ, Su WC, Schuler M, Nam DH, Lim WT, Bauer TM, Azaro A, Poon RTP,
Hong D
, Lin CC, Akimov M, Ghebremariam S, Zhao S, Giovannini M, Ma B. Phase 1 study of capmatinib in MET-positive solid tumor patients: Dose escalation and expansion of selected cohorts. Cancer Sci. 2020 Feb; 111(2):536-547.
PMID:
31778267
; PMCID:
PMC7004521
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Tsimberidou AM
,
Hong DS
, Wheler JJ, Falchook GS,
Janku F
,
Naing A
,
Fu S
,
Piha-Paul S
, Cartwright C,
Broaddus RR
, Nogueras Gonzalez GM,
Hwu P
, Kurzrock R. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145.
PMID:
31888672
; PMCID:
PMC6937824
.
Citations:
10
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Pairawan S,
Hess KR
,
Janku F
, Sanchez NS, Mills Shaw KR,
Eng C
,
Damodaran S
,
Javle M
,
Kaseb AO
,
Hong DS
,
Subbiah V
,
Fu S
,
Fogelman DR
, Raymond VM, Lanman RB,
Meric-Bernstam F
. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res. 2020 04 15; 26(8):1924-1931.
PMID:
31852833
; PMCID:
PMC7771658
.
Citations:
17
Fields:
Neo
Neoplasms
Translation:
Humans
Falchook GS, Kurzrock R,
Amin HM
, Xiong W,
Fu S
,
Piha-Paul SA
,
Janku F
,
Eskandari G
, Catenacci DV, Klevesath M, Bruns R, Stammberger U, Johne A, Bladt F, Friese-Hamim M, Girard P, El Bawab S,
Hong DS
. First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors. Clin Cancer Res. 2020 03 15; 26(6):1237-1246.
PMID:
31822497
.
Citations:
24
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS
, Concin N, Vergote I, de Bono JS, Slomovitz BM, Drew Y, Arkenau HT, Spicer JF, Jones R, Forster MD, Johnson ML, Thistlethwaite FC, Rangwala RA, Ghatta S, Windfeld K, Harris JR, Lassen UN,
Coleman RL
, Machiels JP, Cornez N, Gennigens C. Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer. Clin Cancer Res. 2020 03 15; 26(6):1220-1228.
PMID:
31796521
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Kaizer AM, Koopmeiners JS, Kane MJ, Roychoudhury S,
Hong DS
,
Hobbs BP
. Basket Designs: Statistical Considerations for Oncology Trials. JCO Precis Oncol. 2019 Dec; 3:1-9.
PMID:
35100726
.
Citations:
Fields:
Neo
Neoplasms
Reilley MJ, Morrow B, Ager CR, Liu A,
Hong DS
,
Curran MA
. TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer. 2019 11 26; 7(1):323.
PMID:
31771649
; PMCID:
PMC6880482
.
Citations:
23
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Animals
Cells
George GC
,
Mendoza TR
, Iwuanyanwu EC, Manandhar M, Afshar SF,
Piha-Paul SA
,
Tsimberidou A
,
Naing A
,
Cleeland CS
,
Hong DS
. Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs. 2020 08; 38(4):1166-1174.
PMID:
31761957
; PMCID:
PMC7919140
.
Citations:
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Piha-Paul SA
, Hann CL, French CA, de Bono JS, Harward SD, Ferron-Brady G, Barbash O, Wyce A, Wu Y, Horner T, Annan M, Parr NJ, Prinjha RK, Carpenter CL, Hilton J,
Hong DS
, Haas NB, Markowski MC, Dhar A, O'Dwyer PJ, Shapiro GI, Cousin S, Bra?a I, Cassier PA, Moreno V. Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectr. 2020 Apr; 4(2):pkz093.
PMID:
32328561
; PMCID:
PMC7165800
.
Citations:
44
Fields:
Neo
Neoplasms
Hong DS
. Targeting the KRAS G12C mutation in patients with advanced solid tumors. Clin Adv Hematol Oncol. 2019 Nov; 17(11):612-614.
PMID:
31851163
.
Citations:
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, Gaida K, Holt T, Knutson CG, Koppada N, Lanman BA, Werner J, Rapaport AS, San Miguel T, Ortiz R, Osgood T, Sun JR, Zhu X, McCarter JD, Volak LP, Houk BE, Fakih MG, O'Neil BH, Price TJ, Falchook GS, Desai J, Kuo J, Govindan R,
Hong DS
, Ouyang W, Henary H, Arvedson T, Cee VJ, Lipford JR. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019 11; 575(7781):217-223.
PMID:
31666701
.
Citations:
451
Fields:
Sci
Science
Translation:
Humans
Animals
Cells
CT
Clinical Trials
Welsh JW
, Tang C,
de Groot P
,
Naing A
,
Hess KR
,
Heymach JV
,
Papadimitrakopoulou VA
, Cushman TR,
Subbiah V
,
Chang JY
,
Simon GR
, Ramapriyan R, Barsoumian HB, Menon H,
Cortez MA
, Massarelli E, Nguyen Q,
Sharma P
,
Allison JP
,
Diab A
, Verma V,
Raju U
, Shaaban SG,
Dadu R
,
Cabanillas ME
, Wang K, Anderson C,
Gomez DR
,
Hahn S
,
Komaki R
,
Hong DS
. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res. 2019 12; 7(12):1903-1909.
PMID:
31658994
; PMCID:
PMC6891218
.
Citations:
23
Fields:
All
Allergy and Immunology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe K, Flynn DL, Kaufman MD, Henry JR, Peng SB, Benhadji KA, Conti I, Gordon MS, Tiu RV,
Hong DS
. A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Mol Cancer Ther. 2020 02; 19(2):460-467.
PMID:
31645440
.
Citations:
19
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Cells
CT
Clinical Trials
Dumbrava EEI, Balaji K,
Raghav K
, Hess K,
Javle M
, Blum-Murphy M,
Ajani J
, Kopetz S,
Broaddus R
,
Routbort M
, Demirhan M, Zheng X,
Pant S
,
Tsimberidou AM
,
Subbiah V
,
Hong DS
, Rodon J, Shaw KM,
Piha-Paul SA
,
Meric-Bernstam F
. Targeting ERBB2 (HER2) Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. JCO Precis Oncol. 2019; 3.
PMID:
32923865
; PMCID:
PMC7446516
.
Citations:
4
Fields:
Neo
Neoplasms
Habra MA
, Stephen B, Campbell M, Hess K,
Tapia C
, Xu M, Rodon Ahnert J,
Jimenez C
, Lee JE,
Perrier ND
, Boraddus RR,
Pant S
,
Subbiah V
,
Hong DS
, Zarifa A,
Fu S
,
Karp DD
,
Meric-Bernstam F
,
Naing A
. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019 09 18; 7(1):253.
PMID:
31533818
; PMCID:
PMC6751592
.
Citations:
32
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Menon H, Chen D, Ramapriyan R, Verma V, Barsoumian HB, Cushman TR, Younes AI,
Cortez MA
,
Erasmus JJ
,
de Groot P
,
Carter BW
,
Hong DS
,
Glitza IC
,
Ferrarotto R
, Altan M,
Diab A
,
Chun SG
,
Heymach JV
, Tang C, Nguyen QN,
Welsh JW
. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. J Immunother Cancer. 2019 09 04; 7(1):237.
PMID:
31484556
; PMCID:
PMC6727581
.
Citations:
25
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Adashek JJ, LoRusso PM,
Hong DS
, Kurzrock R. Phase?I trials as valid therapeutic options for patients with cancer. Nat Rev Clin Oncol. 2019 12; 16(12):773-778.
PMID:
31477881
; PMCID:
PMC6868302
.
Citations:
22
Fields:
Neo
Neoplasms
Translation:
Humans
Maymani H, Hess K, Groisberg R,
Hong DS
,
Naing A
,
Piha-Paul S
,
Janku F
,
Fu S
,
Tsimberidou AM
,
Pant S
,
Karp D
, Liu S, Sun M,
Heymach J
,
Simon G
,
Meric-Bernstam F
,
Subbiah V
. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer. 2019 Oct; 136:158.
PMID:
31445783
.
Citations:
Fields:
Neo
Neoplasms
Xing Y, Lin NU, Maurer MA, Chen H,
Mahvash A
,
Sahin A
,
Akcakanat A
, Li Y, Abramson V,
Litton J
, Chavez-MacGregor M,
Valero V
,
Piha-Paul SA
,
Hong D
,
Do KA
, Tarco E, Riall D,
Eterovic AK
, Wulf GM, Cantley LC,
Mills GB
, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM,
Meric-Bernstam F
. Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
PMID:
31277699
; PMCID:
PMC6612080
.
Citations:
52
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong D
, Choi KH, Song YB, Lee JM, Park TK, Yang JH, Hahn JY, Choi JH, Choi SH, Kim SM, Choe Y, Kim EK, Chang SA, Lee SC, Oh JK, Gwon HC. Prognostic implications of post-percutaneous coronary intervention neutrophil-to-lymphocyte ratio on infarct size and clinical outcomes in patients with acute myocardial infarction. Sci Rep. 2019 07 04; 9(1):9646.
PMID:
31273274
; PMCID:
PMC6609693
.
Citations:
6
Fields:
Sci
Science
Translation:
Humans
Cells
Hong D
, Rasco D, Veeder M, Luke JJ, Chandler J, Balmanoukian A, George TJ, Munster P, Berlin JD, Gutierrez M, Mita A, Wakelee H, Samakoglu S, Guan S, Dimery I, Graef T, Borazanci E. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors. Oncology. 2019; 97(2):102-111.
PMID:
31230047
.
Citations:
29
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Vishnoi M, Liu NH, Yin W, Boral D, Scamardo A,
Hong D
, Marchetti D. The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling. Mol Oncol. 2019 09; 13(9):1913-1926.
PMID:
31216110
; PMCID:
PMC6717757
.
Citations:
16
Fields:
Mol
Molecular Biology
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Chun IY,
Hong D
, Adcock B, Fessler JA. Convolutional Analysis Operator Learning: Dependence on Training Data. IEEE Signal Process Lett. 2019 Aug; 26(8):1137-1141.
PMID:
32313415
; PMCID:
PMC7170269
.
Citations:
2
Park A, Chute C, Rajpurkar P, Lou J, Ball RL, Shpanskaya K, Jabarkheel R, Kim LH, McKenna E, Tseng J, Ni J, Wishah F, Wittber F,
Hong DS
, Wilson TJ, Halabi S, Basu S, Patel BN, Lungren MP, Ng AY, Yeom KW. Deep Learning-Assisted Diagnosis of Cerebral Aneurysms Using the HeadXNet Model. JAMA Netw Open. 2019 06 05; 2(6):e195600.
PMID:
31173130
; PMCID:
PMC6563570
.
Citations:
38
Fields:
Med
Medicine (General)
Translation:
Humans
George GC
, Barata PC, Campbell A, Chen A,
Cortes JE
, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA,
Cleeland CS
,
Hong DS
. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev. 2019 Jun; 76:33-40.
PMID:
31108240
.
Citations:
8
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
George GC
, Iwuanyanwu EC, Buford AS,
Piha-Paul SA
,
Subbiah V
,
Fu S
,
Karp DD
,
Pant S
, Hinojosa CO,
Hess KR
,
Cleeland CS
,
Bernstam EV
,
Meric-Bernstam F
,
Hong DS
. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348.
PMID:
30869638
; PMCID:
PMC6437608
.
Citations:
5
Fields:
Med
Medical Informatics
Translation:
Humans
Garrido-Laguna I, Krop I, Burris HA, Hamilton E, Braiteh F, Weise AM, Abu-Khalaf M, Werner TL, Pirie-Shepherd S, Zopf CJ, Lakshminarayanan M, Holland JS, Baffa R,
Hong DS
. First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 10 01; 145(7):1798-1808.
PMID:
30680712
; PMCID:
PMC6875752
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
CT
Clinical Trials
Hegde A,
Hong DS
, Behrang A, Ali SM, Juckett L,
Meric-Bernstam F
,
Subbiah V
. Activity of Brigatinib in Crizotinib and Ceritinib-Resistant ROS1- Rearranged Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3.
PMID:
32775947
; PMCID:
PMC7410165
.
Citations:
1
Fields:
Neo
Neoplasms
de Bono JS, Concin N,
Hong DS
, Thistlethwaite FC, Arkenau HT, Plummer R, Jones RH, Nielsen D, Windfeld K, Ghatta S, Slomovitz BM, Spicer JF, Yachnin J, Ang JE, Forster MD, Collins D, Rangwala RA, Lassen U, Machiels JP, Mau-S?rensen PM, Dean E. Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial. Lancet Oncol. 2019 03; 20(3):383-393.
PMID:
30745090
.
Citations:
40
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Subbiah V
, Anderson PM, Kairemo K, Hess K,
Huh WW
,
Ravi V
, Daw NC,
Somaiah N
,
Ludwig JA
, Benjamin RS, Chawla S,
Hong DS
,
Meric-Bernstam F
,
Ravizzini G
,
Kleinerman E
,
Macapinlac H
, Rohren E. Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. Clin Cancer Res. 2019 07 01; 25(13):3802-3810.
PMID:
30733229
; PMCID:
PMC6606382
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hobbs BP
, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W,
Hong DS
, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst. 2019 02 01; 111(2):118-128.
PMID:
30561713
; PMCID:
PMC6376915
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Bauer TM, Lee JJ, Dowlati A, Brose MS, Farago AF, Taylor M, Shaw AT, Montez S,
Meric-Bernstam F
, Smith S, Tuch BB, Ebata K, Cruickshank S, Cox MC, Burris HA, Doebele RC. Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study. Ann Oncol. 2019 02 01; 30(2):325-331.
PMID:
30624546
; PMCID:
PMC6386027
.
Citations:
30
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Fu C, Gombos DS, Lee J,
George GC
, Hess K, Whyte A,
Hong DS
. Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2019 01 29; 10(9):1011-1013.
PMID:
30847029
; PMCID:
PMC6398178
.
Citations:
Fields:
Neo
Neoplasms
Palaskas N, Morgan J, Daigle T,
Banchs J
, Durand JB,
Hong D
,
Naing A
, Le H,
Hassan SA
,
Karimzad K
,
Mouhayar E
, Kim P,
Lopez-Mattei J
, Thompson K,
Yusuf SW
,
Iliescu C
. Targeted Cancer Therapies With Pericardial Effusions Requiring Pericardiocentesis Focusing on Immune Checkpoint Inhibitors. Am J Cardiol. 2019 04 15; 123(8):1351-1357.
PMID:
30765065
.
Citations:
16
Fields:
Car
Cardiology
Translation:
Humans
George GC
, Buford A, Hess K,
Piha-Paul SA
, Zinner R,
Subbiah V
, Hinojosa C,
Cleeland CS
,
Meric-Bernstam F
,
Bernstam EV
,
Hong DS
. Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clin Cancer Inform. 2018 12; 2:1-14.
PMID:
30652565
; PMCID:
PMC6874009
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
Reilley MJ, McCoon P, Cook C, Lyne P, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J,
Fowler N
, Curran M, Liu Q, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG,
Fayad L
,
Piha-Paul S
, Nadella MVP, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR,
Hong DS
. STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial. J Immunother Cancer. 2018 11 16; 6(1):119.
PMID:
30446007
; PMCID:
PMC6240242
.
Citations:
83
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Hong DS
, LoRusso P, Hamid O,
Janku F
, Kittaneh M, Catenacci DVT, Chan E, Bekaii-Saab T, Gadgeel SM, Loberg RD, Amore BM, Hwang YC, Tang R, Ngarmchamnanrith G, Kwak EL. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2019 Apr 15; 25(8):2403-2413.
PMID:
30425090
; PMCID:
PMC6892342
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
McKean M, Oba J, Ma J, Roth KG, Wang WL, Carapeto FCL, Haydu LE, Siroy AE, Vo P,
Hong DS
,
Eterovic AK
, Patel KP, Bassett RL,
Grimm EA
,
Lazar AJ
,
Woodman SE
, Macedo MP. Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma. J Invest Dermatol. 2019 03; 139(3):728-731.
PMID:
30798855
.
Citations:
4
Fields:
Der
Dermatology
Translation:
Humans
Sandoval GM, Shim S,
Hong DS
, Garrett AS, Quintin EM, Marzelli MJ, Patnaik S, Lightbody AA, Reiss AL. Neuroanatomical abnormalities in fragile X syndrome during the adolescent and young adult years. J Psychiatr Res. 2018 12; 107:138-144.
PMID:
30408626
; PMCID:
PMC6249038
.
Citations:
6
Fields:
Psy
Psychiatry
Translation:
Humans
Hinchcliff E,
Hong D
, Le H, Chisholm G,
Iyer R
,
Naing A
,
Hwu P
,
Jazaeri A
. Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018 12; 151(3):407-413.
PMID:
30366646
; PMCID:
PMC6281778
.
Citations:
7
Fields:
Gyn
Gynecology
Neo
Neoplasms
Translation:
Humans
Subbiah V
, Sen S,
Hess KR
,
Janku F
,
Hong DS
,
Khatua S
,
Karp DD
, Munoz J, Falchook GS, Groisberg R,
Tsimberidou AM
,
Sherman SI
,
Hwu P
,
Meric-Bernstam F
. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With BRAF-Mutated Malignancies. JCO Precis Oncol. 2018; 2.
PMID:
32913986
; PMCID:
PMC7446411
.
Citations:
4
Fields:
Neo
Neoplasms
Wang Y, Wang Z,
Piha-Paul S
,
Janku F
,
Subbiah V
, Shi N, Hess K,
Broaddus R
, Shan B,
Naing A
,
Hong D
,
Tsimberidou AM
,
Karp D
,
Lu C
, Papadimitrakopoulou V,
Heymach J
,
Meric-Bernstam F
,
Fu S
. Outcome analysis of Phase I trial patients with metastatic KRAS and/or TP53 mutant non-small cell lung cancer. Oncotarget. 2018 Sep 07; 9(70):33258-33270.
PMID:
30279957
; PMCID:
PMC6161801
.
Citations:
4
Fields:
Neo
Neoplasms
Fountzilas E, Krishnan E,
Janku F
,
Fu S
,
Karp DD
,
Naing A
,
Subbiah V
,
Hong DS
,
Piha-Paul SA
,
Vining DJ
,
Tsimberidou AM
. A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. Cancer Chemother Pharmacol. 2018 11; 82(5):877-885.
PMID:
30182147
.
Citations:
3
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Dembla V,
Somaiah N
, Barata P, Hess K,
Fu S
,
Janku F
,
Karp DD
,
Naing A
,
Piha-Paul SA
,
Subbiah V
,
Tsimberidou AM
, Shaw K,
Meric-Bernstam F
,
Hong DS
. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 2018 Sep 04; 9(69):33232-33243.
PMID:
30237864
; PMCID:
PMC6145698
.
Citations:
6
Fields:
Neo
Neoplasms
Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M,
Fu S
,
Janku F
, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB,
Hong D
. Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 09; 82(3):419.
PMID:
30014222
; PMCID:
PMC6829701
.
Citations:
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Basho RK, Yam C,
Gilcrease M
,
Murthy RK
, Helgason T,
Karp DD
,
Meric-Bernstam F
,
Hess KR
,
Valero V
,
Albarracin C
,
Litton JK
, Chavez-MacGregor M,
Hong D
, Kurzrock R, Hortobagyi GN,
Janku F
,
Moulder SL
. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. Oncologist. 2018 11; 23(11):1300-1309.
PMID:
30139837
; PMCID:
PMC6291334
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
Subbiah V
,
Murthy R
,
Hong DS
, Prins RM,
Hosing C
, Hendricks K, Kolli D, Noffsinger L, Brown R, McGuire M, Fu S,
Piha-Paul S
,
Naing A
,
Conley AP
, Benjamin RS, Kaur I, Bosch ML. Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. Clin Cancer Res. 2018 08 15; 24(16):3845-3856.
PMID:
30018119
; PMCID:
PMC6449174
.
Citations:
16
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Kheder ES,
Hong DS
. Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins. Clin Cancer Res. 2018 12 01; 24(23):5807-5814.
PMID:
29986850
.
Citations:
31
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Parseghian CM,
Patnana M
, Bhosale P,
Hess KR
,
Shih YT
, Kim B, Kopetz S,
Overman MJ
,
Varadhachary GR
,
Javle M
,
Naing A
,
Piha-Paul S
,
Hong D
, Le H,
Subbiah V
,
Pant S
. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. J Immunother. 2018 Jul/Aug; 41(6):284-291.
PMID:
29668571
; PMCID:
PMC6028046
.
Citations:
3
Fields:
All
Allergy and Immunology
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
Subbiah IM
, Tang C, Rao A, Falchook GS,
Subbiah V
,
Tsimberidou AM
,
Karp D
, Kurzrock R,
Hong DS
. Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget. 2018 Jun 22; 9(48):28842-28848.
PMID:
29989021
; PMCID:
PMC6034739
.
Citations:
3
Fields:
Neo
Neoplasms
Patnaik A, Gordon M, Tsai F, Papadopoulos KP, Rasco D, Beeram M,
Fu S
,
Janku F
, Hynes SM, Gundala SR, Willard MD, Zhang W, Lin AB,
Hong D
. A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. Cancer Chemother Pharmacol. 2018 09; 82(3):407-418.
PMID:
29926131
; PMCID:
PMC6105165
.
Citations:
20
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Oba J, Kim SH, Wang WL, Macedo MP, Carapeto F, McKean MA, Van Arnam J,
Eterovic AK
, Sen S, Kale CR, Yu X,
Haymaker CL
,
Routbort M
, Haydu LE,
Bernatchez C
,
Lazar AJ
,
Grimm EA
,
Hong DS
,
Woodman SE
. Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma. JCO Precis Oncol. 2018; 2018.
PMID:
30094412
; PMCID:
PMC6080631
.
Citations:
9
Fields:
Neo
Neoplasms
Radke JB, Worth D,
Hong D
, Huang S, Sullivan WJ, Wilson EH, White MW. Transcriptional repression by ApiAP2 factors is central to chronic toxoplasmosis. PLoS Pathog. 2018 05; 14(5):e1007035.
PMID:
29718996
; PMCID:
PMC5951591
.
Citations:
35
Fields:
Mic
Microbiology
Translation:
Humans
Animals
Cells
Ghosh P, Chandler AG,
Hobbs BP
, Sun J, Rong J,
Hong D
,
Subbiah V
,
Janku F
,
Naing A
,
Hwu WJ
,
Ng CS
. Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. J Comput Assist Tomogr. 2018 May/Jun; 42(3):357-364.
PMID:
29189398
; PMCID:
PMC5951718
.
Citations:
Fields:
Rad
Radiology
Translation:
Humans
Raghav K
, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R,
Hong D
. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev. 2018 May; 66:95-103.
PMID:
29730462
.
Citations:
8
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Sen S, Kato S, Agarwal R,
Piha-Paul S
, Hess K,
Karp D
,
Janku F
,
Fu S
,
Naing A
,
Pant S
, Falchook G, Tang C, Wu X,
Ye Y
,
Tsimberidou A
,
Subbiah V
, Kurzrock R,
Byers L
,
Westin S
, Lim J, Bean S, Bass A, Nguyen L,
Meric-Bernstam F
,
Hong D
. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. Br J Cancer. 2018 05; 118(11):1419-1424.
PMID:
29695765
; PMCID:
PMC5988803
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Somaiah N
, Beird HC, Barbo A, Song J, Mills Shaw KR, Wang WL, Eterovic K, Chen K,
Lazar A
,
Conley AP
,
Ravi V
,
Hwu P
,
Futreal A
,
Simon G
,
Meric-Bernstam F
,
Hong D
. Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations. Oncotarget. 2018 Apr 13; 9(28):19891-19899.
PMID:
29731991
; PMCID:
PMC5929434
.
Citations:
7
Fields:
Neo
Neoplasms
Groisberg R,
Hong DS
, Roszik J,
Janku F
,
Tsimberidou AM
,
Javle M
,
Meric-Bernstam F
,
Subbiah V
. Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. Mol Cancer Ther. 2018 07; 17(7):1595-1601.
PMID:
29654067
; PMCID:
PMC6310221
.
Citations:
11
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Cells
Hong DS
, Moore K, Patel M, Grant SC, Burris HA, William WN, Jones S,
Meric-Bernstam F
, Infante J, Golden L, Zhang W, Martinez R, Wijayawardana S, Beckmann R, Lin AB,
Eng C
, Bendell J. Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. Clin Cancer Res. 2018 07 15; 24(14):3263-3272.
PMID:
29643063
; PMCID:
PMC6050086
.
Citations:
28
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Maymani H, Hess K, Groisberg R,
Hong DS
,
Naing A
,
Piha-Paul S
,
Janku F
,
Fu S
,
Tsimberidou AM
,
Pant S
,
Karp D
, Liu S, Sun M,
Heymach J
,
Simon G
,
Meric-Bernstam F
,
Subbiah V
. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer. 2018 06; 120:137-141.
PMID:
29748008
; PMCID:
PMC6204221
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Aghajanian C, Bell-McGuinn KM, Burris HA, Siu LL, Stayner LA, Wheler JJ,
Hong DS
, Kurkjian C,
Pant S
, Santiago-Walker A, Gauvin JL, Antal JM, Opalinska JB, Morris SR, Infante JR. A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors. Invest New Drugs. 2018 12; 36(6):1016-1025.
PMID:
29611022
; PMCID:
PMC6170741
.
Citations:
8
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Maitland ML,
Piha-Paul S
, Falchook G, Kurzrock R, Nguyen L, Janisch L, Karovic S, McKee M, Hoening E, Wong S, Munasinghe W, Palma J, Donawho C, Lian GK, Ansell P, Ratain MJ,
Hong D
. Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial. Br J Cancer. 2018 04; 118(8):1042-1050.
PMID:
29551775
; PMCID:
PMC5931107
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER,
Meric-Bernstam F
, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS,
Hong DS
, Hyman DM. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018 02 22; 378(8):731-739.
PMID:
29466156
; PMCID:
PMC5857389
.
Citations:
643
Fields:
Med
Medicine (General)
Translation:
Humans
CT
Clinical Trials
Sen S, Hess K,
Hong DS
,
Naing A
,
Piha-Paul S
,
Janku F
,
Fu S
,
Subbiah IM
, Liu H, Khanji R, Huang L, Moorthy S,
Karp DD
,
Tsimberidou A
,
Meric-Bernstam F
,
Subbiah V
. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. Br J Cancer. 2018 03 20; 118(6):763-769.
PMID:
29462132
; PMCID:
PMC5886120
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Fang L, Chen H,
Tang Z
,
Kalhor N
, Liu CH, Yao H, Hu S, Lin P, Zhao J, Luthra R, Singh RR,
Routbort MJ
,
Hong D
,
Medeiros LJ
, Lu X. MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer. Oncotarget. 2018 Feb 27; 9(16):12959-12970.
PMID:
29560123
; PMCID:
PMC5849187
.
Citations:
4
Fields:
Neo
Neoplasms
Tang C,
Hobbs B
, Amer A, Li X, Behrens C, Canales JR, Cuentas EP, Villalobos P, Fried D,
Chang JY
,
Hong DS
,
Welsh JW
,
Sepesi B
,
Court L
,
Wistuba II
,
Koay EJ
. Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. Sci Rep. 2018 01 31; 8(1):1922.
PMID:
29386574
; PMCID:
PMC5792427
.
Citations:
44
Fields:
Sci
Science
Translation:
Humans
Cells
Bartkowiak T, Jaiswal AR, Ager CR, Chin R, Chen CH, Budhani P, Ai M, Reilley MJ,
Sebastian MM
,
Hong DS
,
Curran MA
. Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway. Clin Cancer Res. 2018 03 01; 24(5):1138-1151.
PMID:
29301830
; PMCID:
PMC6752715
.
Citations:
30
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Groisberg R,
Hong DS
, Behrang A, Hess K,
Janku F
,
Piha-Paul S
,
Naing A
,
Fu S
, Benjamin R,
Patel S
,
Somaiah N
,
Conley A
,
Meric-Bernstam F
,
Subbiah V
. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer. 2017 12 19; 5(1):100.
PMID:
29254498
; PMCID:
PMC5735899
.
Citations:
41
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Sakamuri D,
Glitza IC
,
Betancourt Cuellar SL
,
Subbiah V
,
Fu S
,
Tsimberidou AM
, Wheler JJ,
Hong DS
,
Naing A
, Falchook GS,
Fanale MA
,
Cabanillas ME
,
Janku F
. Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. Mol Cancer Ther. 2018 03; 17(3):671-676.
PMID:
29237802
; PMCID:
PMC5935561
.
Citations:
11
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
CT
Clinical Trials
Dembla V, Groisberg R, Hess K,
Fu S
, Wheler J,
Hong DS
,
Janku F
, Zinner R,
Piha-Paul SA
,
Ravi V
, Benjamin RS,
Patel S
,
Somaiah N
,
Herzog CE
,
Karp DD
, Roszik J,
Meric-Bernstam F
,
Subbiah V
. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Sci Rep. 2017 11 21; 7(1):15963.
PMID:
29162825
; PMCID:
PMC5698336
.
Citations:
14
Fields:
Sci
Science
Translation:
Humans
Cells
Fujii T,
Colen RR
, Bilen MA,
Hess KR
,
Hajjar J
,
Suarez-Almazor ME
, Alshawa A,
Hong DS
,
Tsimberidou A
,
Janku F
, Gong J, Stephen B,
Subbiah V
,
Piha-Paul SA
,
Fu S
,
Sharma P
,
Mendoza T
, Patel A,
Thirumurthi S
,
Sheshadri A
,
Meric-Bernstam F
,
Naing A
. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs. 2018 08; 36(4):638-646.
PMID:
29159766
; PMCID:
PMC5962379
.
Citations:
58
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Colen RR
, Fujii T, Bilen MA, Kotrotsou A, Abrol S,
Hess KR
,
Hajjar J
,
Suarez-Almazor ME
, Alshawa A,
Hong DS
, Giniebra-Camejo D, Stephen B,
Subbiah V
,
Sheshadri A
,
Mendoza T
,
Fu S
,
Sharma P
,
Meric-Bernstam F
,
Naing A
. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018 08; 36(4):601-607.
PMID:
29075985
; PMCID:
PMC5924418
.
Citations:
40
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Kato S, Jardim DL,
Johnson FM
,
Subbiah V
,
Piha-Paul S
,
Tsimberidou AM
, Falchook GS,
Karp D
, Zinner R, Wheler J,
Janku F
,
Fu S
, Lim J, Bean S, Nguyen L, Urban S, Browne E,
Meric-Bernstam F
,
Hong DS
. Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. Invest New Drugs. 2018 06; 36(3):416-423.
PMID:
29047029
; PMCID:
PMC5908757
.
Citations:
10
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Huang HJ,
Hong DS
,
Tsimberidou AM
,
Fu S
,
Piha-Paul SA
,
Subbiah V
,
Karp DD
,
Naing A
, Krug A, Enderle D, Priewasser T, Noerholm M, Eitan E, Coticchia C, Stoll G, Jordan LM,
Eng C
,
Kopetz ES
, Skog J,
Meric-Bernstam F
,
Janku F
, M?hrmann L. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. Clin Cancer Res. 2018 01 01; 24(1):181-188.
PMID:
29051321
; PMCID:
PMC5754253
.
Citations:
63
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Sen S,
Meric-Bernstam F
,
Hong DS
,
Hess KR
,
Subbiah V
. Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. J Natl Cancer Inst. 2017 10 01; 109(10).
PMID:
29117359
; PMCID:
PMC6059192
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Johnson A, Khotskaya YB, Brusco L, Zeng J, Holla V, Bailey AM, Litzenburger BC, Sanchez N, Shufean MA,
Piha-Paul S
,
Subbiah V
,
Hong D
,
Routbort M
,
Broaddus R
, Mills Shaw KR,
Mills GB
,
Mendelsohn J
,
Meric-Bernstam F
. Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017.
PMID:
30320296
; PMCID:
PMC6179148
.
Citations:
12
Fields:
Neo
Neoplasms
Tsimberidou AM
,
Hong DS
, Ye Y, Cartwright C, Wheler JJ, Falchook GS,
Naing A
,
Fu S
,
Piha-Paul S
,
Janku F
,
Meric-Bernstam F
,
Hwu P
,
Kee B
,
Kies MS
,
Broaddus R
,
Mendelsohn J
,
Hess KR
, Kurzrock R. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. JCO Precis Oncol. 2017; 2017.
PMID:
29082359
; PMCID:
PMC5659750
.
Citations:
62
Fields:
Neo
Neoplasms
Boral D, Vishnoi M,
Liu HN
, Yin W, Sprouse ML, Scamardo A,
Hong DS
, Tan TZ, Thiery JP, Chang JC, Marchetti D. Molecular characterization of breast cancer CTCs associated with brain metastasis. Nat Commun. 2017 08 04; 8(1):196.
PMID:
28775303
; PMCID:
PMC5543046
.
Citations:
78
Fields:
Bio
Biology
Sci
Science
Translation:
Humans
Cells
Goldstein JB, Tang C,
Hess KR
,
Hong D
,
Subbiah V
,
Janku F
,
Fu S
,
Karp DD
,
Naing A
,
Tsimberidou AM
, Wheler J, Zinner R,
Javle M
,
Varadhachary GR
,
Wolff RA
,
Fogelman DR
,
Meric-Bernstam F
,
Piha-Paul SA
. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 2017 Oct 20; 8(50):87163-87173.
PMID:
29152071
; PMCID:
PMC5675623
.
Citations:
Fields:
Neo
Neoplasms
Kehl KL, Fullmer CP,
Fu S
,
George GC
,
Hess KR
,
Janku F
,
Karp DD
, Kato S, Kizer CK, Kurzrock R,
Naing A
,
Pant S
,
Piha-Paul SA
,
Subbiah V
,
Tsimberidou AM
,
Hong DS
. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162.
PMID:
28729355
; PMCID:
PMC5902668
.
Citations:
1
Fields:
Neo
Neoplasms
Subbiah IM
,
Tsimberidou A
,
Subbiah V
,
Janku F
, Roy-Chowdhuri S,
Hong DS
. Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. Oncoscience. 2017 May; 4(5-6):47-56.
PMID:
28781987
; PMCID:
PMC5538848
.
Citations:
12
Groisberg R,
Hong DS
, Holla V,
Janku F
,
Piha-Paul S
,
Ravi V
, Benjamin R, Kumar Patel S,
Somaiah N
,
Conley A
, Ali SM, Schrock AB, Ross JS, Stephens PJ, Miller VA, Sen S,
Herzog C
,
Meric-Bernstam F
,
Subbiah V
. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. Oncotarget. 2017 Jun 13; 8(24):39254-39267.
PMID:
28424409
; PMCID:
PMC5503611
.
Citations:
29
Fields:
Neo
Neoplasms
Translation:
Humans
Schroeder RD,
Choi W
,
Hong DS
, McConkey DJ. Autophagy is required for crizotinib-induced apoptosis in MET-amplified gastric cancer cells. Oncotarget. 2017 Aug 01; 8(31):51675-51687.
PMID:
28881678
; PMCID:
PMC5584279
.
Citations:
6
Fields:
Neo
Neoplasms
Sundar R,
Hong DS
, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov. 2017 06; 7(6):558-560.
PMID:
28576843
; PMCID:
PMC5458523
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Janku F
, Zhang S, Waters J, Liu L, Huang HJ,
Subbiah V
,
Hong DS
,
Karp DD
,
Fu S
, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y,
Javle M
,
Kopetz ES
,
Luthra R
, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R,
Heymach JV
,
Meric-Bernstam F
,
Mills GB
, Fan JB, Salathia NS. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
PMID:
28536309
; PMCID:
PMC5600825
.
Citations:
27
Fields:
Neo
Neoplasms
Translation:
Humans
Wang Z,
Piha-Paul S
,
Janku F
,
Subbiah V
, Shi N, Gong J, Wathoo C, Shaw K, Hess K,
Broaddus R
,
Naing A
,
Hong D
,
Tsimberidou AM
,
Karp D
,
Yao J
,
Meric-Bernstam F
,
Fu S
. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. 2017 May 16; 8(20):33796-33806.
PMID:
28430579
; PMCID:
PMC5464912
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Fu C, Gombos DS, Lee J,
George GC
, Hess K, Whyte A,
Hong DS
. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017 Aug 29; 8(35):58709-58727.
PMID:
28938590
; PMCID:
PMC5601686
.
Citations:
8
Fields:
Neo
Neoplasms
Cox VL
, Bhosale P,
Varadhachary GR
,
Wagner-Bartak N
,
Glitza IC
, Gold KA, Atkins JT,
Soliman PT
,
Hong DS
,
Qayyum A
. Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers. Radiology. 2017 05; 283(2):314-340.
PMID:
28418819
.
Citations:
5
Fields:
Rad
Radiology
Translation:
Humans
Subbiah V
, Khawaja MR,
Hong DS
,
Amini B
, Yungfang J, Liu H, Johnson A, Schrock AB, Ali SM, Sun JX, Fabrizio D,
Piha-Paul S
,
Fu S
,
Tsimberidou AM
,
Naing A
,
Janku F
,
Karp DD
,
Overman M
,
Eng C
, Kopetz S,
Meric-Bernstam F
, Falchook GS. First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. JCI Insight. 2017 Apr 20; 2(8).
PMID:
28422758
; PMCID:
PMC5396533
.
Citations:
13
Fields:
Med
Medicine (General)
Reilley MJ, Bailey A,
Subbiah V
,
Janku F
,
Naing A
, Falchook G,
Karp D
,
Piha-Paul S
,
Tsimberidou A
,
Fu S
, Lim J, Bean S, Bass A, Montez S, Vence L,
Sharma P
,
Allison J
,
Meric-Bernstam F
,
Hong DS
. Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies. J Immunother Cancer. 2017; 5:35.
PMID:
28428884
; PMCID:
PMC5394629
.
Citations:
24
Fields:
Neo
Neoplasms
The
Therapeutics
Translation:
Humans
CT
Clinical Trials
Hess K, Zer A,
Meric-Bernstam F
, Siu LL, Razak ARA,
Hong DS
, Bugano DDG, Jardim DLF. Use of Expansion Cohorts in Phase I Trials and Probability of Success in Phase II for 381 Anticancer Drugs. Clin Cancer Res. 2017 Aug 01; 23(15):4020-4026.
PMID:
28377482
; PMCID:
PMC5540786
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Basho RK,
Gilcrease M
,
Murthy RK
, Helgason T,
Karp DD
,
Meric-Bernstam F
,
Hess KR
, Herbrich SM,
Valero V
,
Albarracin C
,
Litton JK
, Chavez-MacGregor M,
Ibrahim NK
, Murray JL,
Koenig KB
,
Hong D
,
Subbiah V
, Kurzrock R,
Janku F
,
Moulder SL
. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol. 2017 Apr 01; 3(4):509-515.
PMID:
27893038
.
Citations:
64
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Porta R, Borea R, Coelho A, Khan S, Reclusa P, Franchina T, Van Der Steen N, Van Dam P, Ferri J, Sirera R,
Naing A
,
Hong D
, Rolfo C, Ara?jo A. FGFR a promising druggable target in cancer: Molecular biology and new drugs. Crit Rev Oncol Hematol. 2017 May; 113:256-267.
PMID:
28427515
.
Citations:
82
Fields:
Hem
Hematology
Neo
Neoplasms
Translation:
Humans
Cells
Tolcher AW, Berlin JD, Cosaert J, Kauh J, Chan E,
Piha-Paul SA
, Amaya A, Tang S, Driscoll K, Kimbung R, Kambhampati SR, Gueorguieva I,
Hong DS
. A phase 1 study of anti-TGF? receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2017 04; 79(4):673-680.
PMID:
28280971
; PMCID:
PMC5893148
.
Citations:
28
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Tang C,
Sherman SI
, Price M, Weng J, Davis SE,
Hong DS
,
Yao JC
,
Buzdar A
,
Wilding G
,
Lee JJ
. Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement. Clin Cancer Res. 2017 Mar 15; 23(6):1414-1421.
PMID:
28275168
; PMCID:
PMC5354950
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
Wagner AJ, Banerji U, Mahipal A,
Somaiah N
, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S,
Hong DS
. Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. J Clin Oncol. 2017 Apr 20; 35(12):1304-1311.
PMID:
28240971
; PMCID:
PMC5946729
.
Citations:
41
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Khotskaya YB, Holla VR, Farago AF, Mills Shaw KR,
Meric-Bernstam F
,
Hong DS
. Targeting TRK family proteins in cancer. Pharmacol Ther. 2017 May; 173:58-66.
PMID:
28174090
.
Citations:
77
Fields:
Dru
Drug Therapy
Pha
Pharmacology
The
Therapeutics
Translation:
Humans
Animals
Tang C,
Welsh JW
,
Hong D
. Phase I Trial: SABR and Ipilimumab-Response. Clin Cancer Res. 2017 01 01; 23(1):321.
PMID:
28049161
; PMCID:
PMC5215783
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Shi E, Chmielecki J, Tang CM, Wang K, Heinrich MC, Kang G, Corless CL,
Hong D
, Fero KE, Murphy JD, Fanta PT, Ali SM, De Siena M, Burgoyne AM, Movva S, Madlensky L, Heestand GM, Trent JC, Kurzrock R, Morosini D, Ross JS, Harismendy O, Sicklick JK. FGFR1 and NTRK3 actionable alterations in "Wild-Type" gastrointestinal stromal tumors. J Transl Med. 2016 12 14; 14(1):339.
PMID:
27974047
; PMCID:
PMC5157084
.
Citations:
74
Fields:
Med
Medicine (General)
Translation:
Humans
Beg MS, Brenner AJ, Sachdev J, Borad M, Kang YK, Stoudemire J, Smith S, Bader AG, Kim S,
Hong DS
. Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors. Invest New Drugs. 2017 04; 35(2):180-188.
PMID:
27917453
; PMCID:
PMC5893501
.
Citations:
306
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Wang Z, Shi N,
Naing A
,
Janku F
,
Subbiah V
,
Araujo DM
,
Patel SR
,
Ludwig JA
,
Ramondetta LM
,
Levenback CF
,
Ramirez PT
,
Piha-Paul SA
,
Hong D
,
Karp DD
,
Tsimberidou AM
,
Meric-Bernstam F
,
Fu S
. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
PMID:
27882721
; PMCID:
PMC5224847
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Tang C,
Hess KR
, Sanders D, Davis SE,
Buzdar AU
, Kurzrock R, Lee JJ,
Meric-Bernstam F
,
Hong DS
. Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual. Clin Cancer Res. 2017 Mar 15; 23(6):1407-1413.
PMID:
27852698
; PMCID:
PMC5872813
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S,
Hong DS
,
Naing A
,
Fu S
,
Tsimberidou AM
,
Piha-Paul S
,
Janku F
,
Karp D
, Reddy S,
Yennu S
,
Epner D
,
Bruera E
,
Meric-Bernstam F
, Falchook G,
Subbiah V
. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. 2017; 92(1):14-20.
PMID:
27802448
; PMCID:
PMC5308283
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Subbiah V
,
Hess KR
, Khawaja MR, Wagner MJ, Tang C,
Naing A
,
Fu S
,
Janku F
,
Piha-Paul S
,
Tsimberidou AM
,
Herzog CE
,
Ludwig JA
,
Patel S
,
Ravi V
, Benjamin RS,
Meric-Bernstam F
,
Hong DS
. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep. 2016 10 17; 6:35448.
PMID:
27748430
; PMCID:
PMC5066200
.
Citations:
7
Fields:
Sci
Science
Translation:
Humans
Subbiah IM
, Wheler JJ,
Hess KR
,
Hong DS
,
Naing A
,
Fu S
, Kurzrock R,
Tsimberidou AM
. Outcomes of patients =65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER. Int J Cancer. 2017 Jan 01; 140(1):208-215.
PMID:
27599876
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
,
Morris VK
, El Osta B, Sorokin AV,
Janku F
,
Fu S
,
Overman MJ
,
Piha-Paul S
,
Subbiah V
,
Kee B
,
Tsimberidou AM
,
Fogelman D
, Bellido J,
Shureiqi I
, Huang H, Atkins J, Tarcic G, Sommer N, Lanman R,
Meric-Bernstam F
, Kopetz S. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. Cancer Discov. 2016 12; 6(12):1352-1365.
PMID:
27729313
; PMCID:
PMC5562357
.
Citations:
100
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
CT
Clinical Trials
Park H, Garrido-Laguna I,
Naing A
,
Fu S
, Falchook GS,
Piha-Paul SA
, Wheler JJ,
Hong DS
,
Tsimberidou AM
,
Subbiah V
, Zinner RG,
Kaseb AO
,
Patel S
,
Fanale MA
, Velez-Bravo VM,
Meric-Bernstam F
, Kurzrock R,
Janku F
. Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget. 2016 Oct 11; 7(41):67521-67531.
PMID:
27589687
; PMCID:
PMC5341894
.
Citations:
24
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Naing A
, Papadopoulos KP, Autio KA, Ott PA, Patel MR, Wong DJ, Falchook GS,
Pant S
, Whiteside M, Rasco DR, Mumm JB, Chan IH, Bendell JC, Bauer TM,
Colen RR
,
Hong DS
, Van Vlasselaer P,
Tannir NM
, Oft M, Infante JR. Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors. J Clin Oncol. 2016 10 10; 34(29):3562-3569.
PMID:
27528724
; PMCID:
PMC5657013
.
Citations:
72
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Bupathi M,
Hajjar J
, Bean S,
Fu S
,
Hong D
,
Karp D
, Stephen B, Hess K,
Meric-Bernstam F
,
Naing A
. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Invest New Drugs. 2017 02; 35(1):59-67.
PMID:
27687047
; PMCID:
PMC5896759
.
Citations:
1
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Livingston JA,
Hess KR
,
Naing A
,
Hong DS
,
Patel S
, Benjamin RS,
Ludwig JA
,
Conley A
,
Herzog CE
, Anderson P,
Meric-Bernstam F
, Kurzrock R,
Subbiah V
. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. 2016 Sep 27; 7(39):64421-64430.
PMID:
27486883
; PMCID:
PMC5325454
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
Tang C,
Welsh JW
,
de Groot P
, Massarelli E,
Chang JY
,
Hess KR
, Basu S,
Curran MA
,
Cabanillas ME
,
Subbiah V
,
Fu S
,
Tsimberidou AM
,
Karp D
,
Gomez DR
,
Diab A
,
Komaki R
,
Heymach JV
,
Sharma P
,
Naing A
,
Hong DS
. Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clin Cancer Res. 2017 Mar 15; 23(6):1388-1396.
PMID:
27649551
; PMCID:
PMC5355002
.
Citations:
137
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Barata P,
Sood AK
,
Hong DS
. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions. Cancer Treat Rev. 2016 Nov; 50:35-47.
PMID:
27612280
.
Citations:
58
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Raghav K
,
Morris V
, Tang C, Morelli P,
Amin HM
, Chen K, Manyam GC,
Broom B
,
Overman MJ
, Shaw K,
Meric-Bernstam F
,
Maru D
,
Menter D
,
Ellis LM
,
Eng C
,
Hong D
, Kopetz S. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. Oncotarget. 2016 08 23; 7(34):54627-54631.
PMID:
27421137
; PMCID:
PMC5342368
.
Citations:
23
Fields:
Neo
Neoplasms
Translation:
Humans
Jardim DL, Schwaederle M,
Hong DS
, Kurzrock R. An appraisal of drug development timelines in the Era of precision oncology. Oncotarget. 2016 Aug 16; 7(33):53037-53046.
PMID:
27419632
; PMCID:
PMC5288167
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
Wheler JJ,
Janku F
,
Naing A
, Li Y, Stephen B, Zinner R,
Subbiah V
,
Fu S
,
Karp D
, Falchook GS,
Tsimberidou AM
,
Piha-Paul S
, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ,
Hong D
, Kurzrock R. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. Mol Cancer Ther. 2016 10; 15(10):2475-2485.
PMID:
27466356
.
Citations:
39
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Cells
George GC
, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG,
Piha-Paul SA
,
Tsimberidou AM
,
Naing A
,
Fu S
,
Janku F
,
Subbiah V
,
Cleeland CS
,
Mendoza TR
,
Hong DS
. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409.
PMID:
27412379
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Liu MC, Yang SJ,
Hong D
, Yang JP, Liu M, Lin Y, Huang CH, Wang CJ. A simple and convenient method for the preparation of antioxidant peptides from walnut (Juglans regia L.) protein hydrolysates. Chem Cent J. 2016; 10:39.
PMID:
27335584
; PMCID:
PMC4916535
.
Citations:
6
Rolfo C, Bretel D,
Hong D
, Raez LE, Oton AB, Gomez H, Dafni U, Vallejos C, Zielinski C, Caglevic C, Cardona AF. Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015. ESMO Open. 2016; 1(4):e000055.
PMID:
27843620
; PMCID:
PMC5070258
.
Citations:
10
Bilen MA, Patel A,
Hess KR
, Munoz J,
Busaidy NL
, Wheler JJ,
Janku F
, Falchook GS,
Hong DS
,
Meric-Bernstam F
,
Habra MA
,
Naing A
. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemother Pharmacol. 2016 07; 78(1):167-71.
PMID:
27286994
.
Citations:
3
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Hou MM, Wang Z,
Janku F
,
Piha-Paul S
,
Naing A
,
Hong D
,
Westin S
,
Coleman RL
,
Sood AK
,
Tsimberidou AM
,
Subbiah V
, Wheler J, Zinner R,
Lu K
,
Meric-Bernstam F
,
Fu S
. Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. Oncotarget. 2016 Jun 07; 7(23):35132-43.
PMID:
27147567
; PMCID:
PMC5085215
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
Janku F
, Huang HJ, Claes B, Falchook GS,
Fu S
,
Hong D
, Ramzanali NM, Nitti G, Cabrilo G,
Tsimberidou AM
,
Naing A
,
Piha-Paul SA
, Wheler JJ,
Karp DD
, Holley VR, Zinner RG,
Subbiah V
,
Luthra R
, Kopetz S,
Overman MJ
,
Kee BK
, Patel S, Devogelaere B, Sablon E, Maertens G,
Mills GB
, Kurzrock R,
Meric-Bernstam F
. BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404.
PMID:
27207774
.
Citations:
43
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Cells
Wheler JJ,
Janku F
,
Naing A
, Li Y, Stephen B, Zinner R,
Subbiah V
,
Fu S
,
Karp D
, Falchook GS,
Tsimberidou AM
,
Piha-Paul S
, Anderson R, Ke D, Miller V, Yelensky R, Lee JJ,
Hong DS
, Kurzrock R. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. Cancer Res. 2016 07 01; 76(13):3690-701.
PMID:
27197177
.
Citations:
109
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Van Der Steen N, Giovannetti E, Pauwels P, Peters GJ,
Hong DS
, Cappuzzo F, Hirsch FR, Rolfo C. cMET Exon 14 Skipping: From the Structure to the Clinic. J Thorac Oncol. 2016 09; 11(9):1423-32.
PMID:
27223456
.
Citations:
20
Fields:
Neo
Neoplasms
Pul
Pulmonary Medicine
Translation:
Humans
Cells
Giallombardo M, Taverna S, Alessandro R,
Hong D
, Rolfo C. Exosome-mediated drug resistance in cancer: the near future is here. Ther Adv Med Oncol. 2016 Sep; 8(5):320-2.
PMID:
27583023
; PMCID:
PMC4981289
.
Citations:
15
Liu X, Kambrick S,
Fu S
,
Naing A
,
Subbiah V
,
Blumenschein GR
,
Glisson BS
,
Kies MS
,
Tsimberidou AM
, Wheler JJ, Zinner RG,
Hong DS
, Kurzrock R,
Piha-Paul SA
. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. Oncotarget. 2016 Apr 26; 7(17):23227-38.
PMID:
26933802
; PMCID:
PMC5029622
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Said R, Kakadiaris E,
Piha-Paul S
,
Fu S
, Falchook G,
Janku F
, Wheler JJ, Zinner R,
Hong DS
, Kurzrock R,
Tsimberidou AM
. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102.
PMID:
27085994
.
Citations:
2
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Parsons HA, Baracos VE,
Hong DS
, Abbruzzese J,
Bruera E
, Kurzrock R. The effects of curcumin (diferuloylmethane) on body composition of patients with advanced pancreatic cancer. Oncotarget. 2016 Apr 12; 7(15):20293-304.
PMID:
26934122
; PMCID:
PMC4991455
.
Citations:
11
Fields:
Neo
Neoplasms
Translation:
Humans
Hong D
, Infante J,
Janku F
, Jones S, Nguyen LM, Burris H,
Naing A
, Bauer TM,
Piha-Paul S
,
Johnson FM
, Kurzrock R, Golden L, Hynes S, Lin J, Lin AB, Bendell J. Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016 05 20; 34(15):1764-71.
PMID:
27044938
; PMCID:
PMC5321045
.
Citations:
63
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Fu S
, Culotta KS, Falchook GS,
Hong DS
, Myers AL, Zhang YP,
Naing A
,
Janku F
, Hou MM, Kurzrock R. Erratum to: Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Apr; 77(4):881.
PMID:
26994910
.
Citations:
1
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Khawaja MR, Nick AM, Madhusudanannair V,
Fu S
,
Hong D
, McQuinn LM,
Ng CS
,
Piha-Paul SA
,
Janku F
,
Subbiah V
,
Tsimberidou A
,
Karp D
,
Meric-Bernstam F
,
Lu KH
,
Naing A
. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.
PMID:
27014780
; PMCID:
PMC5978416
.
Citations:
19
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Subbiah V
,
Hong DS
,
Meric-Bernstam F
. Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. Proc Natl Acad Sci U S A. 2016 Mar 15; 113(11):E1419-20.
PMID:
26917690
; PMCID:
PMC4801313
.
Citations:
14
Fields:
Sci
Science
Translation:
Humans
Sloane D, Govindarajulu U, Harrow-Mortelliti J, Barry W, Hsu FI,
Hong D
, Laidlaw T, Palis R, Legere H, Bunyavanich S, Breslow R, Wesemann D, Barrett N, Brennan P, Chong HJ, Liu A, Fernandez J, Fanning L, Kyin T, Cahill K, Bankova L, Lynch A, Berlin S, Campos S, Fuchs C, Mayer R, Matulonis U, Castells M. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
PMID:
26895621
.
Citations:
37
Fields:
All
Allergy and Immunology
Translation:
Humans
Said R, Ye Y,
Hong DS
,
Naing A
, Falchook G,
Fu S
, Wheler JJ,
Piha-Paul S
,
Tsimberidou AM
. Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 Mar; 77(3):575-81.
PMID:
26825327
.
Citations:
3
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Siqing F, Culotta KS, Falchook GS,
Hong DS
, Myers AL, Zhang YP,
Naing A
,
Janku F
, Hou MM, Kurzrock R. Pharmacokinetic evaluation of nanoparticle albumin-bound paclitaxel delivered via hepatic arterial infusion in patients with predominantly hepatic metastases. Cancer Chemother Pharmacol. 2016 Feb; 77(2):357-64.
PMID:
26698868
.
Citations:
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS
, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L,
George GC
, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 2015 Dec 15; 6(40):43127-34.
PMID:
26503473
; PMCID:
PMC4767496
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Vishnoi M, Peddibhotla S, Yin W, T Scamardo A,
George GC
,
Hong DS
, Marchetti D. The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep. 2015 Dec 03; 5:17533.
PMID:
26631983
; PMCID:
PMC4668355
.
Citations:
54
Fields:
Sci
Science
Translation:
Humans
Cells
Munster P, Aggarwal R,
Hong D
, Schellens JH, van der Noll R, Specht J, Witteveen PO, Werner TL, Dees EC, Bergsland E, Agarwal N, Kleha JF, Durante M, Adams L, Smith DA, Lampkin TA, Morris SR, Kurzrock R. First-in-Human Phase I Study of GSK2126458, an Oral Pan-Class I Phosphatidylinositol-3-Kinase Inhibitor, in Patients with Advanced Solid Tumor Malignancies. Clin Cancer Res. 2016 Apr 15; 22(8):1932-9.
PMID:
26603258
.
Citations:
34
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong D
, Kurzrock R, Kim Y, Woessner R, Younes A, Nemunaitis J,
Fowler N
, Zhou T, Schmidt J, Jo M, Lee SJ, Yamashita M, Hughes SG,
Fayad L
,
Piha-Paul S
, Nadella MV, Mohseni M, Lawson D, Reimer C, Blakey DC, Xiao X, Hsu J, Revenko A, Monia BP, MacLeod AR. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015 Nov 18; 7(314):314ra185.
PMID:
26582900
; PMCID:
PMC5279222
.
Citations:
179
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Animals
Cells
CT
Clinical Trials
Fu S
, Shi N, Wheler J,
Naing A
,
Janku F
,
Piha-Paul S
, Gong J,
Hong D
,
Tsimberidou A
, Zinner R,
Subbiah V
, Hou MM,
Ramirez P
,
Ramondetta L
,
Lu K
,
Meric-Bernstam F
. Characteristics and outcomes for patients with advanced vaginal or vulvar cancer referred to a phase I clinical trials program: the MD Anderson cancer center experience. Gynecol Oncol Res Pract. 2015; 2:10.
PMID:
27231570
; PMCID:
PMC4880813
.
Citations:
5
Janku F
, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M,
Naing A
, Fu S,
Piha-Paul SA
,
Hong DS
, Holley VR,
Tsimberidou AM
, Stepanek VM,
Patel SP
, Kopetz ES,
Subbiah V
, Wheler JJ, Zinner RG,
Karp DD
,
Luthra R
, Roy-Chowdhuri S, Sablon E,
Meric-Bernstam F
, Maertens G, Kurzrock R. BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. Oncotarget. 2015 Sep 29; 6(29):26886-94.
PMID:
26330075
; PMCID:
PMC4694960
.
Citations:
17
Fields:
Neo
Neoplasms
Translation:
Humans
Subbiah IM
, Falchook GS,
Kaseb AO
,
Hess KR
,
Tsimberidou AM
,
Fu S
,
Subbiah V
,
Hong DS
,
Naing A
,
Piha-Paul SA
, Akmal O,
Janku F
, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 2015 Sep 29; 6(29):28453-62.
PMID:
26164085
; PMCID:
PMC4695071
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Jardim DL, Fontes Jardim DL, Schwaederle M, Wei C,
Lee JJ
,
Hong DS
, Eggermont AM, Schilsky RL,
Mendelsohn J
, Lazar V, Kurzrock R. Impact of a Biomarker-Based Strategy on Oncology Drug Development: A Meta-analysis of Clinical Trials Leading to FDA Approval. J Natl Cancer Inst. 2015 Nov; 107(11).
PMID:
26378224
; PMCID:
PMC4857149
.
Citations:
75
Fields:
Neo
Neoplasms
Translation:
Humans
Janku F
, Angenendt P,
Tsimberidou AM
, Fu S,
Naing A
, Falchook GS,
Hong DS
, Holley VR, Cabrilo G, Wheler JJ,
Piha-Paul SA
, Zinner RG, Bedikian AY,
Overman MJ
,
Kee BK
, Kim KB, Kopetz ES,
Luthra R
, Diehl F,
Meric-Bernstam F
, Kurzrock R. Erratum: Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 Sep 15; 6(27):24581.
PMID:
26405159
; PMCID:
PMC4695208
.
Citations:
1
Fields:
Neo
Neoplasms
Seyedin SN, Schoenhals JE, Lee DA,
Cortez MA
, Wang X, Niknam S, Tang C,
Hong DS
,
Naing A
,
Sharma P
,
Allison JP
,
Chang JY
,
Gomez DR
,
Heymach JV
,
Komaki RU
, Cooper LJ, Welsh JW. Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy. 2015; 7(9):967-980.
PMID:
26310908
; PMCID:
PMC4825325
.
Citations:
31
Fields:
All
Allergy and Immunology
The
Therapeutics
Translation:
Humans
Animals
Cells
Boland GM,
Piha-Paul SA
,
Subbiah V
,
Routbort M
, Herbrich SM,
Baggerly K
,
Patel KP
, Brusco L, Horombe C,
Naing A
, Fu S,
Hong DS
,
Janku F
, Johnson A,
Broaddus R
, Luthra R, Shaw K,
Mendelsohn J
,
Mills GB
,
Meric-Bernstam F
. Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
PMID:
26015395
; PMCID:
PMC4652990
.
Citations:
26
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS
, Rosen P, Lockhart AC,
Fu S
,
Janku F
, Kurzrock R, Khan R, Amore B, Caudillo I, Deng H, Hwang YC, Loberg R, Ngarmchamnanrith G, Beaupre DM, Lee P. A first-in-human study of AMG 208, an oral MET inhibitor, in adult patients with advanced solid tumors. Oncotarget. 2015 Jul 30; 6(21):18693-706.
PMID:
26155941
; PMCID:
PMC4621921
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS
, Kurzrock R, Wheler JJ,
Naing A
, Falchook GS,
Fu S
, Kim KB,
Davies MA
, Nguyen LM,
George GC
, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10.
PMID:
26169970
; PMCID:
PMC4840931
.
Citations:
24
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Subbiah V
, Bupathi M, Kato S, Livingston A,
Slopis J
, Anderson PM,
Hong DS
. Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. Oncoscience. 2015; 2(7):646-58.
PMID:
26328274
; PMCID:
PMC4549362
.
Citations:
3
Busaidy NL
, LoRusso P, Lawhorn K,
Hess KR
, Habra MA,
Fu S
,
Hong DS
, Chen HX, Doyle LA, Kurzrock R,
Naing A
. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. Oncologist. 2015 Jul; 20(7):737-41.
PMID:
26054632
; PMCID:
PMC4492245
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Meric-Bernstam F
, Brusco L, Shaw K, Horombe C, Kopetz S,
Davies MA
,
Routbort M
,
Piha-Paul SA
,
Janku F
,
Ueno N
,
Hong D
,
De Groot J
,
Ravi V
, Li Y, Luthra R, Patel K,
Broaddus R
,
Mendelsohn J
,
Mills GB
. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
PMID:
26014291
; PMCID:
PMC4550690
.
Citations:
203
Fields:
Neo
Neoplasms
Translation:
Humans
Said R, Kurzrock R,
Naing A
,
Hong DS
,
Fu S
,
Piha-Paul SA
, Wheler JJ,
Janku F
,
Kee BK
, Bidyasar S, Lim J, Wallace M,
Tsimberidou AM
. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver. Invest New Drugs. 2015 Aug; 33(4):911-20.
PMID:
25990659
; PMCID:
PMC4492845
.
Citations:
3
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Janku F
, Angenendt P,
Tsimberidou AM
,
Fu S
,
Naing A
, Falchook GS,
Hong DS
, Holley VR, Cabrilo G, Wheler JJ,
Piha-Paul SA
, Zinner RG, Bedikian AY,
Overman MJ
,
Kee BK
, Kim KB,
Kopetz ES
,
Luthra R
, Diehl F,
Meric-Bernstam F
, Kurzrock R. Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies. Oncotarget. 2015 May 20; 6(14):12809-21.
PMID:
25980577
; PMCID:
PMC4494976
.
Citations:
50
Fields:
Neo
Neoplasms
Translation:
Humans
Ke D, Lim J, Stephen B, Bellido J,
Janku F
, Zinner R,
Tsimberidou A
,
Hong D
,
Piha-Paul S
,
Fu S
,
Naing A
,
Subbiah V
,
Karp D
, Falchook G, Kurzrock R, Wheler J, Rodrigues HV. Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. Invest New Drugs. 2015 Jun; 33(3):700-9.
PMID:
25902899
.
Citations:
10
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Meric-Bernstam F
, Johnson A, Holla V, Bailey AM, Brusco L,
Chen K
,
Routbort M
,
Patel KP
, Zeng J,
Kopetz S
,
Davies MA
,
Piha-Paul SA
,
Hong DS
,
Eterovic AK
,
Tsimberidou AM
,
Broaddus R
,
Bernstam EV
, Shaw KR,
Mendelsohn J
,
Mills GB
. A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
PMID:
25863335
; PMCID:
PMC4651038
.
Citations:
91
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Hong DS
,
Janku F
,
Naing A
, Falchook GS,
Piha-Paul S
, Wheler JJ,
Fu S
,
Tsimberidou AM
, Stecher M, Mohanty P, Simard J, Kurzrock R. Xilonix, a novel true human antibody targeting the inflammatory cytokine interleukin-1 alpha, in non-small cell lung cancer. Invest New Drugs. 2015 Jun; 33(3):621-31.
PMID:
25822109
; PMCID:
PMC4482235
.
Citations:
20
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Wheler J, Yelensky R, Falchook G, Kim KB,
Hwu P
,
Tsimberidou AM
, Stephens PJ,
Hong D
, Cronin MT, Kurzrock R. Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer. 2015 Feb 18; 15:61.
PMID:
25886620
; PMCID:
PMC4340232
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
Naing A
,
Dalal S
, Abdelrahim M, Wheler J,
Hess K
,
Fu S
,
Hong DS
,
Janku F
, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Support Care Cancer. 2015 Sep; 23(9):2649-54.
PMID:
25680763
.
Citations:
8
Fields:
Neo
Neoplasms
Pal
Palliative Care
Translation:
Humans
CT
Clinical Trials
Bilen MA,
Fu S
, Falchook GS,
Ng CS
, Wheler JJ, Abdelrahim M, Erguvan-Dogan B,
Hong DS
,
Tsimberidou AM
, Kurzrock R,
Naing A
. Phase I trial of valproic acid and lenalidomide in patients with advanced cancer. Cancer Chemother Pharmacol. 2015 Apr; 75(4):869-74.
PMID:
25666183
.
Citations:
12
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Jain RK,
Hong DS
,
Naing A
, Wheler J, Helgason T, Shi NY, Gad Y, Kurzrock R. Novel phase I study combining G1 phase, S phase, and G2/M phase cell cycle inhibitors in patients with advanced malignancies. Cell Cycle. 2015; 14(21):3434-40.
PMID:
26467427
; PMCID:
PMC4825574
.
Citations:
2
Fields:
Cel
Cell Biology
Translation:
Humans
CT
Clinical Trials
Falchook GS, Millward M,
Hong D
,
Naing A
,
Piha-Paul S
,
Waguespack SG
,
Cabanillas ME
,
Sherman SI
, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid. 2015 Jan; 25(1):71-7.
PMID:
25285888
; PMCID:
PMC4291160
.
Citations:
58
Fields:
End
Endocrinology
Translation:
Humans
Churi CR,
Shroff R
, Wang Y,
Rashid A
, Kang HC, Weatherly J, Zuo M, Zinner R,
Hong D
,
Meric-Bernstam F
,
Janku F
, Crane CH, Mishra L, Vauthey JN,
Wolff RA
,
Mills G
,
Javle M
. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
PMID:
25536104
; PMCID:
PMC4275227
.
Citations:
170
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Cells
Hou MM, Liu X, Wheler J,
Naing A
,
Hong D
,
Coleman RL
,
Tsimberidou A
,
Janku F
, Zinner R,
Lu K
, Kurzrock R,
Fu S
. Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience. Oncotarget. 2014 Nov 30; 5(22):11168-79.
PMID:
25426553
; PMCID:
PMC4294378
.
Citations:
34
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS
, Kurzrock R, Mulay M, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Rosen LS. A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours. Oncotarget. 2014 Nov 30; 5(22):11154-67.
PMID:
25525888
; PMCID:
PMC4294348
.
Citations:
8
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Falchook GS, Wheler JJ,
Naing A
, Jackson EF,
Janku F
,
Hong D
,
Ng CS
,
Tannir NM
, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL,
Amin HM
, Kurzrock R. Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92.
PMID:
25373733
; PMCID:
PMC4279372
.
Citations:
22
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Falchook GS, Wheler JJ,
Naing A
,
Piha-Paul SA
,
Fu S
,
Tsimberidou AM
,
Hong DS
,
Janku F
, Zinner R, Jiang Y, Huang M, Lin Q, Parkhurst K, Kurzrock R. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors. Invest New Drugs. 2015 Feb; 33(1):215-24.
PMID:
25363205
; PMCID:
PMC4477529
.
Citations:
5
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Falchook GS,
Moulder S
,
Naing A
, Wheler JJ,
Hong DS
,
Piha-Paul SA
,
Tsimberidou AM
,
Fu S
, Zinner R,
Janku F
, Jiang Y, Huang M, Parkhurst KL, Kurzrock R. A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs. 2015 Feb; 33(1):177-86.
PMID:
25323060
; PMCID:
PMC4297242
.
Citations:
7
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K,
Janku F
,
Fu S
, Wheler JJ, Zinner RG,
Naing A
,
Tsimberidou AM
, Holla V, Li MM, Roy-Chowdhuri S,
Luthra R
, Salgia R, Kurzrock R,
Meric-Bernstam F
,
Hong DS
. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clin Cancer Res. 2014 Dec 15; 20(24):6336-45.
PMID:
25326232
.
Citations:
41
Fields:
Neo
Neoplasms
Translation:
Humans
Rolfo C,
Hong D
, Alessandro R, Mertens I, Baggerman G, Zwaenepoel K, Carreca AP, Taverna S, Vento R, Santini D, Peeters M, Pauwels P, Castiglia M, Gil-Bazo I, Passiglia F, Russo A. Liquid biopsies in lung cancer: the new ambrosia of researchers. Biochim Biophys Acta. 2014 Dec; 1846(2):539-46.
PMID:
25444714
.
Citations:
75
Fields:
Bio
Biochemistry
Bio
Biophysics
Translation:
Humans
Animals
Cells
Said R, Ye Y, Falchook GS,
Janku F
,
Naing A
, Zinner R,
Blumenschein GR
,
Fu S
,
Hong DS
,
Piha-Paul SA
, Wheler JJ, Kurzrock R, Palmer GA, Aldape K,
Hess KR
,
Tsimberidou AM
. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 2014 Oct 15; 5(19):8937-46.
PMID:
25313136
; PMCID:
PMC4253408
.
Citations:
6
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Tang C, Hess K, Jardim DL, Gagliato Dde M,
Tsimberidou AM
, Falchook G,
Fu S
,
Janku F
,
Naing A
,
Piha-Paul S
,
Subbiah V
, Wheler J, Zinner RG, Kurzrock R,
Ellis LM
, Meric-Berstam F,
Hong DS
. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clin Cancer Res. 2014 Dec 01; 20(23):5956-63.
PMID:
25316815
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Ganesan P,
Moulder S
,
Lee JJ
,
Janku F
,
Valero V
, Zinner RG,
Naing A
,
Fu S
,
Tsimberidou AM
,
Hong D
, Stephen B, Stephens P, Yelensky R,
Meric-Bernstam F
, Kurzrock R, Wheler JJ. Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agents. Mol Cancer Ther. 2014 Dec; 13(12):3175-84.
PMID:
25253784
; PMCID:
PMC4258414
.
Citations:
16
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Cells
Tang C, Wang X, Soh H, Seyedin S,
Cortez MA
,
Krishnan S
, Massarelli E,
Hong D
,
Naing A
,
Diab A
,
Gomez D
, Ye H,
Heymach J
,
Komaki R
,
Allison JP
,
Sharma P
,
Welsh JW
. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
PMID:
25187273
; PMCID:
PMC5367158
.
Citations:
132
Fields:
All
Allergy and Immunology
Neo
Neoplasms
Translation:
Humans
Animals
Falchook GS,
Naing A
, Wheler JJ,
Tsimberidou AM
, Zinner R,
Hong DS
, Fu S,
Piha-Paul SA
,
Janku F
, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 2014; 1(8):540-9.
PMID:
25594061
; PMCID:
PMC4278330
.
Citations:
9
Corrales-Medina FF,
Herzog C
, Hess K, Egas-Bejar D,
Hong DS
, Falchook G, Anderson P,
Nunez C
,
Huh WW
,
Naing A
,
Tsimberidou AM
, Wheler J, Paul SP,
Janku F
,
Kleinerman ES
, Kurzrock R,
Subbiah V
. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 2014 Jul 27; 1(7):522-530.
PMID:
25587555
; PMCID:
PMC4278323
.
Citations:
2
Tang C,
Liao Z
,
Gomez D
, Levy L, Zhuang Y, Gebremichael RA,
Hong DS
,
Komaki R
,
Welsh JW
. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
PMID:
25035212
.
Citations:
120
Fields:
Neo
Neoplasms
Rad
Radiology
Rad
Radiotherapy
Translation:
Humans
Jardim DL, Falchook G, Zinner R, Wheler JJ,
Janku F
,
Subbiah V
,
Piha-Paul SA
,
Fu S
,
Tannir N
,
Corn P
, Tang C,
Hess K
, Roy-Chowdhuri S, Kurzrock R,
Meric-Bernstam F
,
Hong DS
, de Melo Gagliato D. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clin Genitourin Cancer. 2015 Feb; 13(1):e19-26.
PMID:
25087088
; PMCID:
PMC5144738
.
Citations:
10
Fields:
Neo
Neoplasms
Uro
Urology
Translation:
Humans
Nunez MI
, Jelinek J,
Hong D
, Gupta S, Aldaz M, Issa JP, Kurzrock R,
Wistuba II
, Stewart DJ. Impact of decitabine on immunohistochemistry expression of the putative tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor samples. Clin Epigenetics. 2014; 6(1):13.
PMID:
25024751
; PMCID:
PMC4094901
.
Citations:
6
Fields:
Gen
Genetics
Tetzlaff MT
, Nicholson K,
Duvic M
, Kim KB, Tsai KY,
Hwu WJ
,
Hong DS
,
Prieto VG
, Torres-Cabala CA,
Curry JL
. Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy. Am J Dermatopathol. 2014 Jul; 36(7):557-61.
PMID:
24950418
.
Citations:
2
Fields:
Der
Dermatology
Pat
Pathology
Translation:
Humans
Tsimberidou AM
, Wen S,
Hong DS
, Wheler JJ, Falchook GS,
Fu S
,
Piha-Paul S
,
Naing A
,
Janku F
, Aldape K, Ye Y, Kurzrock R,
Berry D
. Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. Clin Cancer Res. 2014 Sep 15; 20(18):4827-36.
PMID:
24987059
; PMCID:
PMC4518867
.
Citations:
98
Fields:
Neo
Neoplasms
Translation:
Humans
de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ,
Janku F
,
Subbiah V
,
Piha-Paul SA
,
Fu S
, Hess K, Roy-Chowdhuri S,
Moulder S
, Gonzalez-Angulo AM,
Meric-Bernstam F
,
Hong DS
. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clin Breast Cancer. 2014 Dec; 14(6):468-74.
PMID:
25065564
; PMCID:
PMC4375949
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Said R, Ye Y,
Hong DS
,
Janku F
,
Fu S
,
Naing A
, Wheler JJ, Kurzrock R, Thomas C, Palmer GA,
Hess KR
, Aldape K,
Tsimberidou AM
. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 2014 Jun 15; 5(11):3871-9.
PMID:
25003695
; PMCID:
PMC4116527
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Henary H, Falchook GS, Naing A,
Fu S
, Moulder S, Wheler JJ,
Tsimberidou A
,
Durand JB
, Khan R,
Yang P
, Johansen M, Newman RA, Kurzrock R. First-in-human study of pbi-05204, an oleander-derived inhibitor of akt, fgf-2, nf-?? and p70s6k, in patients with advanced solid tumors. Invest New Drugs. 2014 Dec; 32(6):1204-12.
PMID:
24919855
.
Citations:
27
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Animals
Cells
CT
Clinical Trials
Rolfo C, Giovannetti E,
Hong DS
, Bivona T, Raez LE, Bronte G, Buffoni L, Santos ES, Germonpre P, Passiglia F, Van Meerbeeck JP, Russo A, Peeters M, Gil-Bazo I, Pauwels P, Rosell R, Reguart N, Taron M. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. Cancer Treat Rev. 2014 Sep; 40(8):990-1004.
PMID:
24953979
.
Citations:
37
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Animals
Falchook G, Kurzrock R, Gouw L,
Hong D
, McGregor KA, Zhou X, Shi H, Fingert H, Sharma S. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study. Invest New Drugs. 2014 Dec; 32(6):1181-7.
PMID:
24879333
; PMCID:
PMC4229392
.
Citations:
21
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Wheler JJ,
Moulder SL
,
Naing A
,
Janku F
,
Piha-Paul SA
, Falchook GS, Zinner R,
Tsimberidou AM
,
Fu S
,
Hong DS
, Atkins JT, Yelensky R, Stephens PJ, Kurzrock R. Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget. 2014 May 30; 5(10):3029-38.
PMID:
24912489
; PMCID:
PMC4102789
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Jacobs C, Tumati V, Kapur P, Yan J,
Hong D
, Bhuiyan M, Xie XJ, Pistenmaa D, Yu L, Hsieh JT, Saha D, Kim DW. DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 2014 Jul 15; 89(4):729-35.
PMID:
24867541
; PMCID:
PMC4464555
.
Citations:
3
Fields:
Neo
Neoplasms
Rad
Radiology
Rad
Radiotherapy
Translation:
Humans
Bendell JC,
Hong DS
, Burris HA,
Naing A
, Jones SF, Falchook G, Bricmont P, Elekes A, Rock EP, Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul; 74(1):125-30.
PMID:
24819685
.
Citations:
53
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hou MM, Liu X, Wheler J,
Naing A
,
Hong D
,
Bodurka D
,
Schmeler K
,
Tsimberidou A
,
Janku F
, Zinner R,
Piha-Paul S
, Hu CY,
Lu K
, Kurzrock R,
Fu S
. Outcomes of patients with metastatic cervical cancer in a phase I clinical trials program. Anticancer Res. 2014 May; 34(5):2349-55.
PMID:
24778042
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Akcakanat A
,
Hong DS
,
Meric-Bernstam F
. Targeting translation initiation in breast cancer. Translation (Austin). 2014; 2(1):e28968.
PMID:
26779407
; PMCID:
PMC4705830
.
Citations:
1
Bilen MA, Durand JB, McQuinn L,
Hess KR
,
Fu S
, Falchook GS,
Hong DS
, Wheler JJ, Said R, Ewer MS, Kurzrock R,
Naing A
. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Invest New Drugs. 2014 Aug; 32(4):717-22.
PMID:
24764123
.
Citations:
1
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Hong DS
,
Hui D
,
Bruera E
,
Janku F
,
Naing A
, Falchook GS,
Piha-Paul S
, Wheler JJ,
Fu S
,
Tsimberidou AM
, Stecher M, Mohanty P, Simard J, Kurzrock R. MABp1, a first-in-class true human antibody targeting interleukin-1a in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol. 2014 May; 15(6):656-66.
PMID:
24746841
.
Citations:
70
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS
, Garrido-Laguna I,
Ekmekcioglu S
, Falchook GS,
Naing A
, Wheler JJ,
Fu S
,
Moulder SL
,
Piha-Paul S
,
Tsimberidou AM
, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W,
George GC
, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73.
PMID:
24752867
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Jardim DL, de Melo Gagliato D, Falchook GS,
Janku F
, Zinner R, Wheler JJ,
Subbiah V
,
Piha-Paul SA
,
Fu S
, Murphy MB,
Ajani J
, Tang C, Hess K,
Hamilton SR
, Roy-Chowdhuri S, Kurzrock R,
Meric-Bernstam F
,
Hong DS
. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 2014 Apr 15; 5(7):1837-45.
PMID:
24742823
; PMCID:
PMC4039117
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Piha-Paul SA
, Wheler JJ,
Fu S
,
Levenback C
,
Lu K
, Falchook GS,
Naing A
,
Hong DS
,
Tsimberidou AM
, Kurzrock R. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus. Oncotarget. 2014 Apr 15; 5(7):1846-55.
PMID:
24742900
; PMCID:
PMC4039109
.
Citations:
9
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Munoz J, Dhillon N,
Janku F
,
Watowich SS
,
Hong DS
. STAT3 inhibitors: finding a home in lymphoma and leukemia. Oncologist. 2014 May; 19(5):536-44.
PMID:
24705981
; PMCID:
PMC4012967
.
Citations:
26
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Liu X, Lorusso P, Mita M,
Piha-Paul S
,
Hong DS
,
Fu S
, McQuinn L, Asatiani E, Doyle LA, Chen HX,
Hess KR
, Kurzrock R,
Naing A
. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014 Apr; 19(4):426-8.
PMID:
24668327
; PMCID:
PMC3983812
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Tang C, Jardim DL,
Hong D
. MET in ovarian cancer: metastasis and resistance? Cell Cycle. 2014; 13(8):1220-1.
PMID:
24621499
; PMCID:
PMC4049955
.
Citations:
4
Fields:
Cel
Cell Biology
Translation:
Humans
Cells
Hong DS
, Hoeft F, Marzelli MJ, Lepage JF, Roeltgen D, Ross J, Reiss AL. Influence of the X-chromosome on neuroanatomy: evidence from Turner and Klinefelter syndromes. J Neurosci. 2014 Mar 05; 34(10):3509-16.
PMID:
24599451
; PMCID:
PMC3942570
.
Citations:
17
Fields:
Neu
Neurology
Translation:
Humans
Cells
Jardim DL, Wheler JJ, Hess K,
Tsimberidou AM
, Zinner R,
Janku F
,
Subbiah V
,
Naing A
,
Piha-Paul SA
,
Westin SN
, Roy-Chowdhuri S,
Meric-Bernstam F
,
Hong DS
. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. PLoS One. 2014; 9(2):e89388.
PMID:
24586741
; PMCID:
PMC3929689
.
Citations:
30
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Tsimberidou AM
, Adamopoulos AM, Ye Y,
Piha-Paul S
,
Janku F
,
Fu S
,
Hong D
, Falchook GS,
Naing A
, Wheler J, Fortier A, Kurzrock R,
Hess KR
. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. J Natl Compr Canc Netw. 2014 Feb; 12(2):194-203.
PMID:
24586081
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Wheler JJ,
Janku F
, Falchook GS, Jackson TL,
Fu S
,
Naing A
,
Tsimberidou AM
,
Moulder SL
,
Hong DS
,
Yang H
,
Piha-Paul SA
, Atkins JT,
Garcia-Manero G
, Kurzrock R. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother Pharmacol. 2014 Mar; 73(3):495-501.
PMID:
24435060
; PMCID:
PMC4148903
.
Citations:
25
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Janku F
,
Hong DS
,
Fu S
,
Piha-Paul SA
,
Naing A
, Falchook GS,
Tsimberidou AM
, Stepanek VM,
Moulder SL
,
Lee JJ
, Zinner RG,
Broaddus RR
, Wheler JJ, Kurzrock R,
Luthra R
. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014 Jan 30; 6(2):377-87.
PMID:
24440717
; PMCID:
PMC4409143
.
Citations:
120
Fields:
Cel
Cell Biology
Mol
Molecular Biology
Translation:
Humans
CT
Clinical Trials
Subbiah V
, Brown RE, McGuire MF, Buryanek J,
Janku F
, Younes A,
Hong D
. A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. Oncotarget. 2014 Jan 15; 5(1):95-102.
PMID:
24395633
; PMCID:
PMC3960191
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Nunez MI
, Jelinek J,
Hong D
, Gupta S, Issa JP,
Wistuba II
, Kurzrock R, Stewart DJ. Decitabine impact on the endocytosis regulator RhoA, the folate carriers RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors. Clin Epigenetics. 2014 Jan 09; 6(1):2.
PMID:
24401732
; PMCID:
PMC3895853
.
Citations:
5
Fields:
Gen
Genetics
Rolfo C, Fanale D,
Hong DS
,
Tsimberidou AM
,
Piha-Paul SA
, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V, Cicero G, Russo A, Giovannetti E. Impact of microRNAs in resistance to chemotherapy and novel targeted agents in non-small cell lung cancer. Curr Pharm Biotechnol. 2014; 15(5):475-85.
PMID:
24846062
.
Citations:
31
Fields:
Bio
Biotechnology
Pha
Pharmacology
Translation:
Humans
Animals
Tang C, Jardim DL, Falchook GS, Hess K,
Fu S
, Wheler JJ, Zinner RG,
Naing A
,
Tsimberidou AM
, De Melo Galgiato D,
Westin SN
,
Meric-Bernstam F
, Kurzrock R,
Hong DS
. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 2014; 1(1):5-13.
PMID:
25593979
; PMCID:
PMC4295762
.
Citations:
19
Naing A
, Agarwal R, Falchook G,
Hong DS
,
Janku F
, Wheler J,
Fu S
, Kurzrock R. Retreatment after secondary resistance or mixed response: a pilot study. Oncology. 2013; 85(6):350-5.
PMID:
24335388
.
Citations:
1
Fields:
Neo
Neoplasms
Translation:
Humans
Fu S
, Hou MM, Wheler J,
Hong D
,
Naing A
,
Tsimberidou A
,
Janku F
, Zinner R,
Piha-Paul S
, Falchook G,
Kuo MT
, Kurzrock R. Exploratory study of carboplatin plus the copper-lowering agent trientine in patients with advanced malignancies. Invest New Drugs. 2014 Jun; 32(3):465-72.
PMID:
24306314
.
Citations:
16
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Schreckinger M, Walker B, Knepper J, Hornyak M,
Hong D
, Kim JM, Folbe A, Guthikonda M, Mittal S, Szerlip NJ. Post-operative diabetes insipidus after endoscopic transsphenoidal surgery. Pituitary. 2013 Dec; 16(4):445-51.
PMID:
23242859
.
Citations:
22
Fields:
End
Endocrinology
Translation:
Humans
Hong DS
, Kurzrock R, Naing A, Wheler JJ, Falchook GS, Schiffman JS, Faulkner N, Pilat MJ, O'Brien J, LoRusso P. A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors. Invest New Drugs. 2014 Jun; 32(3):436-44.
PMID:
24258465
.
Citations:
90
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Cells
CT
Clinical Trials
Hong DS
, Gordon MS, Samlowski WE, Kurzrock R,
Tannir N
, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2014 Jun; 12(3):167-177.e2.
PMID:
24365125
; PMCID:
PMC4754667
.
Citations:
9
Fields:
Neo
Neoplasms
Uro
Urology
Translation:
Humans
CT
Clinical Trials
Jardim DL,
Hess KR
, Lorusso P, Kurzrock R,
Hong DS
. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clin Cancer Res. 2014 Jan 15; 20(2):281-8.
PMID:
24190980
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
Fu S
, McQuinn L,
Naing A
, Wheler JJ,
Janku F
, Falchook GS,
Piha-Paul SA
, Tu D, Howard A,
Tsimberidou A
, Zinner R,
Hong DS
, Kurzrock R. Barriers to study enrollment in patients with advanced cancer referred to a phase I clinical trials unit. Oncologist. 2013; 18(12):1315-20.
PMID:
24153239
; PMCID:
PMC3868426
.
Citations:
13
Fields:
Neo
Neoplasms
Translation:
Humans
Garcia SS, Atkins JT, Falchook GS,
Tsimberidou AM
,
Hong DS
,
Trivedi MV
, Kurzrock R. Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1265-71.
PMID:
24101145
.
Citations:
2
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Ganesan P,
Janku F
,
Naing A
,
Hong DS
,
Tsimberidou AM
, Falchook GS, Wheler JJ,
Piha-Paul SA
,
Fu S
, Stepanek VM,
Lee JJ
,
Luthra R
,
Overman MJ
,
Kopetz ES
,
Wolff RA
, Kurzrock R. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther. 2013 Dec; 12(12):2857-63.
PMID:
24092809
; PMCID:
PMC4158732
.
Citations:
18
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Cells
Gonzalez-Angulo AM,
Meric-Bernstam F
, Chawla S, Falchook G,
Hong D
,
Akcakanat A
, Chen H,
Naing A
,
Fu S
, Wheler J,
Moulder S
, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 01; 19(19):5474-84.
PMID:
24089446
; PMCID:
PMC3935482
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Tsimberidou AM
, Vaklavas C,
Fu S
, Wen S, Lim JA,
Hong D
, Wheler J,
Naing A
, Uehara C, Wallace M, Kurzrock R. Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience. Hepatogastroenterology. 2013 Oct; 60(127):1611-23.
PMID:
24634931
.
Citations:
7
Fields:
Gas
Gastroenterology
Translation:
Humans
Wheler JJ,
Tsimberidou AM
, Falchook GS, Zinner RG,
Hong DS
, Fok JY,
Fu S
,
Piha-Paul SA
,
Naing A
, Kurzrock R. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol Cancer Ther. 2013 Oct; 12(10):2167-75.
PMID:
23963360
; PMCID:
PMC4138057
.
Citations:
17
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
CT
Clinical Trials
Falchook GS,
Fu S
,
Naing A
,
Hong DS
,
Hu W
,
Moulder S
, Wheler JJ,
Sood AK
, Bustinza-Linares E, Parkhurst KL, Kurzrock R. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013 Oct; 31(5):1192-200.
PMID:
23907406
; PMCID:
PMC3809091
.
Citations:
17
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Cells
CT
Clinical Trials
Curry JL
, Torres-Cabala CA, Kim KB,
Tetzlaff MT
,
Duvic M
, Tsai KY,
Hong DS
,
Prieto VG
. Dermatologic toxicities to targeted cancer therapy: shared clinical and histologic adverse skin reactions. Int J Dermatol. 2014 Mar; 53(3):376-84.
PMID:
23879247
.
Citations:
17
Fields:
Der
Dermatology
Translation:
Humans
Cells
Hong D
, Said R, Falchook G,
Naing A
,
Moulder S
,
Tsimberidou AM
, Galluppi G, Dakappagari N, Storgard C, Kurzrock R, Rosen LS. Phase I study of BIIB028, a selective heat shock protein 90 inhibitor, in patients with refractory metastatic or locally advanced solid tumors. Clin Cancer Res. 2013 Sep 01; 19(17):4824-31.
PMID:
23873691
; PMCID:
PMC3935614
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Ganesan P,
Piha-Paul S
,
Naing A
, Falchook G, Wheler J,
Fu S
,
Hong DS
, Kurzrock R,
Janku F
, Laday S, Bedikian AY,
Kies M
,
Wolff RA
,
Tsimberidou AM
. Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer. Invest New Drugs. 2014 Apr; 32(2):279-86.
PMID:
23756764
; PMCID:
PMC5730367
.
Citations:
8
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Wheler J,
Hong D
,
Swisher SG
, Falchook G,
Tsimberidou AM
, Helgason T,
Naing A
, Stephen B,
Janku F
, Stephens PJ, Yelensky R, Kurzrock R. Thymoma patients treated in a phase I clinic at MD Anderson Cancer Center: responses to mTOR inhibitors and molecular analyses. Oncotarget. 2013 Jun; 4(6):890-8.
PMID:
23765114
; PMCID:
PMC3757246
.
Citations:
14
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Wheler J, Falchook G,
Tsimberidou AM
,
Hong D
,
Naing A
,
Piha-Paul S
, Chen SS,
Heymach J
,
Fu S
, Stephen B, Fok JY,
Janku F
, Kurzrock R. Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population. Oncotarget. 2013 May; 4(5):772-84.
PMID:
23800712
; PMCID:
PMC3742837
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Said R,
Hong DS
, Warneke CL,
Lee JJ
, Wheler JJ,
Janku F
,
Naing A
, Falchook GS, Fu S,
Piha-Paul S
,
Tsimberidou AM
, Kurzrock R. P53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013 May; 4(5):705-14.
PMID:
23670029
; PMCID:
PMC3742831
.
Citations:
64
Fields:
Neo
Neoplasms
Translation:
Humans
Jain RK,
Lee JJ
,
Hong D
, Kurzrock R. RE: Meta-analysis of the relationship between dose and benefit in phase I targeted agent trials. J Natl Cancer Inst. 2013 Jun 05; 105(11):833.
PMID:
23628598
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Naing A
,
Fu S
, Zinner RG, Wheler JJ,
Hong DS
, Arakawa K, Falchook GS, Kurzrock R. Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors. Invest New Drugs. 2014 Feb; 32(1):154-9.
PMID:
23609829
; PMCID:
PMC3913855
.
Citations:
4
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
CT
Clinical Trials
Hong DS
,
George GC
, Iwuanyanwu EC, Tavana B, Falchook GS,
Piha-Paul SA
, Wheler JJ, Mistry RH, Lei X, Kurzrock R. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol. 2013 Jun; 139(6):963-70.
PMID:
23455881
.
Citations:
3
Fields:
Neo
Neoplasms
Translation:
Humans
Falchook GS, Rady P,
Hymes S
, Nguyen HP, Tyring SK,
Prieto VG
,
Hong DS
, Kurzrock R. Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenib. JAMA Dermatol. 2013 Mar; 149(3):322-6.
PMID:
23552670
; PMCID:
PMC4085990
.
Citations:
6
Fields:
Der
Dermatology
Translation:
Humans
Cells
Janku F
, Wheler JJ,
Hong DS
, Kurzrock R. Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. Target Oncol. 2013 Sep; 8(3):183-188.
PMID:
23400451
; PMCID:
PMC3766504
.
Citations:
2
Fields:
Neo
Neoplasms
Translation:
Humans
Tsimberidou AM
, Ye Y, Wheler J,
Naing A
,
Hong D
, Nwosu U,
Hess KR
,
Wolff RA
. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemother Pharmacol. 2013 Apr; 71(4):955-63.
PMID:
23377373
; PMCID:
PMC3977741
.
Citations:
5
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Gomez DR
,
Hong DS
, Allen PK,
Welsh JS
,
Mehran RJ
,
Tsao AS
, Liao Z, Bilton SD,
Komaki R
,
Rice DC
. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.
PMID:
23247629
; PMCID:
PMC5610569
.
Citations:
39
Fields:
Neo
Neoplasms
Pul
Pulmonary Medicine
Translation:
Humans
PH
Public Health
Naing A
, Cohen R, Dy GK,
Hong DS
, Dyster L, Hangauer DG, Kwan R, Fetterly G, Kurzrock R, Adjei AA. A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies. Invest New Drugs. 2013 Aug; 31(4):967-73.
PMID:
23361621
.
Citations:
24
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Cells
CT
Clinical Trials
Holsinger FC,
Piha-Paul SA
,
Janku F
,
Hong DS
, Atkins JT,
Tsimberidou AM
, Kurzrock R. Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway. J Clin Oncol. 2013 Mar 20; 31(9):e137-40.
PMID:
23358976
; PMCID:
PMC5950501
.
Citations:
14
Fields:
Neo
Neoplasms
Translation:
Humans
Jain RK,
Lee JJ
,
Hong D
, Kurzrock R. Reply to A. Levy et al. J Clin Oncol. 2013 Jan 20; 31(3):396.
PMID:
23451354
.
Citations:
Fields:
Neo
Neoplasms
Translation:
Humans
Subbiah IM
,
Subbiah V
,
Tsimberidou AM
,
Naing A
,
Kaseb AO
,
Javle M
,
Fu S
,
Hong DS
,
Piha-Paul S
, Wheler JJ,
Hess KR
,
Janku F
, Falchook GS,
Wolff RA
, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
PMID:
23391555
; PMCID:
PMC3702215
.
Citations:
21
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Falchook GS,
Naing A
,
Hong DS
, Zinner R,
Fu S
,
Piha-Paul SA
,
Tsimberidou AM
, Morgan-Linnell SK, Jiang Y, Bastida C, Wheler JJ, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget. 2013 Jan; 4(1):118-27.
PMID:
23435217
; PMCID:
PMC3702212
.
Citations:
20
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Janku F
, Wheler JJ,
Naing A
, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I,
Tsimberidou AM
,
Piha-Paul SA
,
Moulder SL
,
Lee JJ
,
Luthra R
,
Hong DS
, Kurzrock R. PIK3CA mutations in advanced cancers: characteristics and outcomes. Oncotarget. 2012 Dec; 3(12):1566-75.
PMID:
23248156
; PMCID:
PMC3681495
.
Citations:
47
Fields:
Neo
Neoplasms
Translation:
Humans
Yu L, Tumati V, Tseng SF, Hsu FM, Kim DN,
Hong D
, Hsieh JT, Jacobs C, Kapur P, Saha D. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor. Neoplasia. 2012 Dec; 14(12):1203-12.
PMID:
23308052
; PMCID:
PMC3540945
.
Citations:
35
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Hong DS
, Banerji U, Tavana B,
George GC
, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013 Jun; 39(4):375-87.
PMID:
23199899
.
Citations:
100
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
Hong DS
, Choe JH,
Naing A
, Wheler JJ, Falchook GS,
Piha-Paul S
,
Moulder SL
,
George GC
, Choe JM, Strauss LC,
Gallick GE
, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26.
PMID:
23179336
; PMCID:
PMC4482128
.
Citations:
18
Fields:
Ant
Antineoplastic Agents
Pha
Pharmacology
Translation:
Humans
Cells
CT
Clinical Trials
Tsimberidou AM
, Leick MB, Lim J,
Fu S
, Wheler J,
Piha-Paul SA
,
Hong D
, Falchook GS,
Naing A
,
Subbiah IM
, Fortier A,
Avritscher R
, Kurzrock R. Dose-finding study of hepatic arterial infusion of oxaliplatin-based treatment in patients with advanced solid tumors metastatic to the liver. Cancer Chemother Pharmacol. 2013 Feb; 71(2):389-97.
PMID:
23143207
.
Citations:
5
Fields:
Ant
Antineoplastic Agents
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Janku F
, Wheler JJ,
Naing A
, Falchook GS,
Hong DS
, Stepanek VM,
Fu S
,
Piha-Paul SA
,
Lee JJ
,
Luthra R
,
Tsimberidou AM
, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013 Jan 01; 73(1):276-84.
PMID:
23066039
; PMCID:
PMC3537862
.
Citations:
141
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
Tsimberidou AM
, Iskander NG,
Hong DS
, Wheler JJ, Falchook GS,
Fu S
,
Piha-Paul S
,
Naing A
,
Janku F
,
Luthra R
, Ye Y, Wen S,
Berry D
, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012 Nov 15; 18(22):6373-83.
PMID:
22966018
; PMCID:
PMC4454458
.
Citations:
245
Fields:
Neo
Neoplasms
Translation:
Humans
Moroney J,
Fu S
,
Moulder S
, Falchook G, Helgason T,
Levenback C
,
Hong D
,
Naing A
, Wheler J, Kurzrock R. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity. Clin Cancer Res. 2012 Oct 15; 18(20):5796-805.
PMID:
22927482
.
Citations:
39
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Lepage JF, Mazaika PK,
Hong DS
, Raman M, Reiss AL. Cortical brain morphology in young, estrogen-naive, and adolescent, estrogen-treated girls with Turner syndrome. Cereb Cortex. 2013 Sep; 23(9):2159-68.
PMID:
22806268
; PMCID:
PMC3729198
.
Citations:
13
Fields:
Bra
Brain
Translation:
Humans
Fu S
, Barber FD,
Naing A
, Wheler J,
Hong D
, Falchook G,
Piha-Paul S
,
Tsimberidou A
, Howard A, Kurzrock R. Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol. 2012 Aug 10; 30(23):2891-6.
PMID:
22778314
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Bray S, Hoeft F,
Hong DS
, Reiss AL. Aberrant functional network recruitment of posterior parietal cortex in Turner syndrome. Hum Brain Mapp. 2013 Dec; 34(12):3117-28.
PMID:
22711287
; PMCID:
PMC4360970
.
Citations:
14
Fields:
Bra
Brain
Translation:
Humans
Hong DS
, Bowles DW, Falchook GS, Messersmith WA,
George GC
, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82.
PMID:
22693357
.
Citations:
68
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Jain RK,
Lee JJ
,
Ng C
,
Hong D
, Gong J,
Naing A
, Wheler J, Kurzrock R. Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol. 2012 Jul 20; 30(21):2684-90.
PMID:
22689801
; PMCID:
PMC3413279
.
Citations:
38
Fields:
Neo
Neoplasms
Translation:
Humans
Kurzrock R, Goel S, Wheler J,
Hong D
,
Fu S
, Rezai K, Morgan-Linnell SK, Urien S, Mani S, Chaudhary I, Ghalib MH, Buchbinder A, Mulcahy M, Lokiec F. Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies. Cancer. 2012 Dec 15; 118(24):6144-51.
PMID:
22674635
.
Citations:
10
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Tsimberidou AM
,
Fu S
,
Subbiah IM
,
Naing A
,
Hong DS
, Wen S, Fortier AH, Lim J, Kurzrock R. Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosis. Hepatogastroenterology. 2012 Jun; 59(116):960-4.
PMID:
22580643
.
Citations:
1
Fields:
Gas
Gastroenterology
Translation:
Humans
CT
Clinical Trials
Garrido-Laguna I,
Hong DS
,
Janku F
, Nguyen LM, Falchook GS,
Fu S
, Wheler JJ,
Luthra R
,
Naing A
, Wang X, Kurzrock R. KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors. PLoS One. 2012; 7(5):e38033.
PMID:
22675430
; PMCID:
PMC3364990
.
Citations:
23
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Cells
Hong DS
, Kurzrock R, Supko JG, He X,
Naing A
, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J,
Konopleva M
,
Konoplev S
,
Andreeff M
, Kufe D, Lazarus H, Shapiro GI, Dezube BJ. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012 Jun 15; 18(12):3396-406.
PMID:
22634319
; PMCID:
PMC4494099
.
Citations:
94
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Hong DS
, Patel JC, Wheler J,
Naing A
, Garrido-Laguna I, Falchook G,
Fu S
,
Tsimberidou AM
,
Kopetz S
, Win S, Kurzrock R. Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience. Clin Colorectal Cancer. 2012 Dec; 11(4):297-303.
PMID:
22537607
.
Citations:
5
Fields:
Gas
Gastroenterology
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Lopez Guerra JL,
Gomez D
, Zhuang Y,
Hong DS
,
Heymach JV
,
Swisher SG
,
Lin SH
,
Komaki R
, Cox JD,
Liao Z
. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e61-7.
PMID:
22503522
; PMCID:
PMC3919541
.
Citations:
44
Fields:
Neo
Neoplasms
Rad
Radiology
Rad
Radiotherapy
Translation:
Humans
Lin CS, Selch MT, Lee SP, Wu JK, Xiao F,
Hong DS
, Chen CH, Hussain A, Lee PP, De Salles AA. Accelerator-based stereotactic radiosurgery for brainstem metastases. Neurosurgery. 2012 Apr; 70(4):953-8; discussion 958.
PMID:
21997541
.
Citations:
9
Fields:
Neu
Neurosurgery
Translation:
Humans
Naing A
, LoRusso P,
Fu S
,
Hong DS
, Anderson P, Benjamin RS,
Ludwig J
, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012 May 01; 18(9):2625-31.
PMID:
22465830
; PMCID:
PMC3875297
.
Citations:
98
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Wheler J,
Tsimberidou AM
,
Hong D
,
Naing A
, Falchook G,
Piha-Paul S
,
Fu S
,
Moulder S
, Stephen B, Wen S, Kurzrock R. Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res. 2012 May 15; 18(10):2922-9.
PMID:
22452943
; PMCID:
PMC4176886
.
Citations:
42
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Vence L, Falchook G, Radvanyi LG, Liu C, Goodman V, Legos JJ, Blackman S, Scarmadio A, Kurzrock R,
Lizee G
,
Hwu P
. BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012 Apr 15; 18(8):2326-35.
PMID:
22355009
.
Citations:
45
Fields:
Neo
Neoplasms
Translation:
Humans
Cells
CT
Clinical Trials
Janku F
, Wheler JJ,
Westin SN
,
Moulder SL
,
Naing A
,
Tsimberidou AM
,
Fu S
, Falchook GS,
Hong DS
, Garrido-Laguna I,
Luthra R
,
Lee JJ
,
Lu KH
, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol. 2012 Mar 10; 30(8):777-82.
PMID:
22271473
; PMCID:
PMC3295566
.
Citations:
225
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Hallmayer J, Reiss AL, Lepage JF. Genomic imprinting effects on cognitive and social abilities in prepubertal girls with Turner syndrome. J Clin Endocrinol Metab. 2012 Mar; 97(3):E460-4.
PMID:
22238395
; PMCID:
PMC3319213
.
Citations:
9
Fields:
End
Endocrinology
Met
Metabolism
Translation:
Humans
Parsons HA,
Tsimberidou AM
, Pontikos M,
Fu S
,
Hong D
, Wen S, Baracos VE, Kurzrock R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr Cancer. 2012; 64(2):206-17.
PMID:
22229660
; PMCID:
PMC3886552
.
Citations:
6
Fields:
Neo
Neoplasms
Nut
Nutritional Sciences
Translation:
Humans
Parsons HA, Baracos VE, Dhillon N,
Hong DS
, Kurzrock R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One. 2012; 7(1):e29330.
PMID:
22235285
; PMCID:
PMC3250428
.
Citations:
30
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Subbiah V
,
Slopis J
,
Hong DS
,
Ketonen LM
, Hamilton J,
McCutcheon IE
, Kurzrock R. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J Clin Oncol. 2012 Feb 10; 30(5):e64-8.
PMID:
22203760
; PMCID:
PMC3295556
.
Citations:
18
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Munoz J,
Hong D
, Kurzrock R. Anticoagulation-induced severe bleeding in a patient receiving bevacizumab therapy. Int J Hematol. 2012 Jan; 95(1):1-2.
PMID:
22170230
.
Citations:
2
Fields:
Hem
Hematology
Translation:
Humans
El-Osta H, Falchook G,
Tsimberidou A
,
Hong D
,
Naing A
, Kim K, Wen S,
Janku F
, Kurzrock R. BRAF mutations in advanced cancers: clinical characteristics and outcomes. PLoS One. 2011; 6(10):e25806.
PMID:
22039425
; PMCID:
PMC3198456
.
Citations:
35
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Moroney JW, Schlumbrecht MP, Helgason T,
Coleman RL
,
Moulder S
,
Naing A
,
Bodurka DC
,
Janku F
,
Hong DS
, Kurzrock R. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res. 2011 Nov 01; 17(21):6840-6.
PMID:
21890452
; PMCID:
PMC3207033
.
Citations:
23
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
El-Osta H,
Hong D
, Wheler J,
Fu S
,
Naing A
, Falchook G,
Hicks M
, Wen S,
Tsimberidou AM
, Kurzrock R. Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist. 2011; 16(9):1292-8.
PMID:
21859821
; PMCID:
PMC3228176
.
Citations:
24
Fields:
Neo
Neoplasms
Translation:
Humans
Fu S
,
Hong DS
,
Naing A
, Wheler J, Falchook G, Wen S, Howard A, Barber D,
Nates J
,
Price K
, Kurzrock R. Outcome analyses after the first admission to an intensive care unit in patients with advanced cancer referred to a phase I clinical trials program. J Clin Oncol. 2011 Sep 10; 29(26):3547-52.
PMID:
21844494
.
Citations:
12
Fields:
Neo
Neoplasms
Translation:
Humans
Hong DS
, Kurzrock R, Oh Y, Wheler J,
Naing A
, Brail L, Callies S, Kadam SK, Nasir A, Holzer TR,
Meric-Bernstam F
, Fishman M,
Simon G
, Andr? V. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011 Oct 15; 17(20):6582-91.
PMID:
21831956
; PMCID:
PMC5036398
.
Citations:
59
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Garrido-Laguna I,
Janku F
, Vaklavas C, Falchook GS,
Fu S
,
Hong DS
,
Naing A
,
Tsimberidou AM
, Wen S, Kurzrock R. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center. Cancer. 2012 Mar 01; 118(5):1422-8.
PMID:
21823111
.
Citations:
38
Fields:
Neo
Neoplasms
Translation:
Humans
Janku F
,
Lee JJ
,
Tsimberidou AM
,
Hong DS
,
Naing A
, Falchook GS,
Fu S
,
Luthra R
, Garrido-Laguna I, Kurzrock R. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One. 2011; 6(7):e22769.
PMID:
21829508
; PMCID:
PMC3146490
.
Citations:
104
Fields:
Med
Medicine (General)
Sci
Science
Translation:
Humans
Naing A
, Kurzrock R, Burger A, Gupta S, Lei X,
Busaidy N
,
Hong D
, Chen HX, Doyle LA, Heilbrun LK, Rohren E,
Ng C
, Chandhasin C, LoRusso P. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011 Sep 15; 17(18):6052-60.
PMID:
21750201
; PMCID:
PMC3176947
.
Citations:
64
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Galsky MD, Seng S, Camacho LH, Chiorean EG, Mulkerin D,
Hong DS
, Oh WK, Bajorin DF. Retrospective analysis of satraplatin in patients with metastatic urothelial cancer refractory to standard platinum-based chemotherapy. Clin Genitourin Cancer. 2011 Sep; 9(1):27-30.
PMID:
21700509
.
Citations:
1
Fields:
Neo
Neoplasms
Uro
Urology
Translation:
Humans
Kurzrock R,
Sherman SI
, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F,
Hong DS
,
Ng CS
, Ye L,
Gagel RF
, Frye J, Ratain MJ, Salgia R, M?ller T. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
PMID:
21606412
; PMCID:
PMC3646303
.
Citations:
204
Fields:
Neo
Neoplasms
Translation:
Humans
CT
Clinical Trials
Janku F
, McConkey DJ,
Hong DS
, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011 May 17; 8(9):528-39.
PMID:
21587219
.
Citations:
341
Fields:
Neo
Neoplasms
Translation:
Humans
Animals
Cells
Fu S
,
Naing A
,
Moulder SL
, Culotta KS, Madoff DC,
Ng CS
, Madden TL, Falchook GS,
Hong DS
, Kurzrock R. Phase I trial of hepatic arterial infusion of nanoparticle albumin-bound paclitaxel: toxicity, pharmacokinetics, and activity. Mol Cancer Ther. 2011 Jul; 10(7):1300-7.
PMID:
21571911
.
Citations:
9
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
CT
Clinical Trials
Naing A
, Stephen SK, Frenkel M, Chandhasin C,
Hong DS
, Lei X, Falchook G, Wheler JJ,
Fu S
, Kurzrock R. Prevalence of complementary medicine use in a phase 1 clinical trials program: the MD Anderson Cancer Center Experience. Cancer. 2011 Nov 15; 117(22):5142-50.
PMID:
21538342
.
Citations:
27
Fields:
Neo
Neoplasms
Translation:
Humans
Tsimberidou AM
, Letourneau K, Wen S, Wheler J,
Hong D
,
Naing A
, Iskander NG, Uehara C, Kurzrock R. Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience. Clin Cancer Res. 2011 Jun 15; 17(12):4110-8.
PMID:
21415223
; PMCID:
PMC3410654
.
Citations:
7
Fields:
Neo
Neoplasms
Translation:
Humans
Janku F
,
Tsimberidou AM
, Wang X,
Hong DS
,
Naing A
, Gong J, Garrido-Laguna I, Parsons HA, Zinner RG, Kurzrock R. Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist. 2011; 16(3):327-35.
PMID:
21339262
; PMCID:
PMC3228100
.
Citations:
4
Fields:
Neo
Neoplasms
Translation:
Humans
Naing A
, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, Verschraegen C, Stephen S, Aaron J,
Hong D
, Wheler J, Kurzrock R. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. J Cancer. 2011 Feb 10; 2:81-9.
PMID:
21326629
; PMCID:
PMC3039225
.
Citations:
23
Pandey P, Rayes M,
Hong D
, Guthikonda M, Xavier A. Endovascular management of a giant aneurysm through saphenous vein graft after extracranial-intracranial bypass: case report and literature review. J Neurointerv Surg. 2011 Dec 01; 3(4):361-3.
PMID:
21990469
.
Citations:
2
Fields:
Gen
General Surgery
Neu
Neurology
Translation:
Humans
Hong DS
,
Cabanillas ME
, Wheler J,
Naing A
,
Tsimberidou AM
, Ye L,
Busaidy NL
,
Waguespack SG
, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J,
Sherman SI
, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab. 2011 Apr; 96(4):997-1005.
PMID:
21289252
; PMCID:
PMC3070247
.
Citations:
40
Fields:
End
Endocrinology
Met
Metabolism
Translation:
Humans
Cells
CT
Clinical Trials
Piha-Paul SA
,
Hong DS
, Kurzrock R. Response of lymphangioleiomyomatosis to a mammalian target of rapamycin inhibitor (temsirolimus) -based treatment. J Clin Oncol. 2011 Apr 20; 29(12):e333-5.
PMID:
21263090
.
Citations:
5
Fields:
Neo
Neoplasms
Translation:
Humans
Janku F
,
Tsimberidou AM
, Garrido-Laguna I, Wang X,
Luthra R
,
Hong DS
,
Naing A
, Falchook GS, Moroney JW,
Piha-Paul SA
, Wheler JJ,
Moulder SL
,
Fu S
, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther. 2011 Mar; 10(3):558-65.
PMID:
21216929
; PMCID:
PMC3072168
.
Citations:
177
Fields:
Ant
Antineoplastic Agents
Translation:
Humans
Camacho LH, Garcia S, Panchal AM, Lim J,
Hong DS
,
Ng C
, Madoff DC,
Fu S
, Gayed I, Kurzrock R. Exploratory study of hepatic arterial infusion oxaliplatin with systemic 5-fluorouracil/bevacizumab in patients with refractory solid tumor and extensive liver metastases. Clin Colorectal Cancer. 2010 Dec; 9(5):311-4.
PMID:
21208846
; PMCID:
PMC3088086
.
Citations:
1
Fields:
Gas
Gastroenterology
Neo
Neoplasms
Translation:
Humans
Tsimberidou AM
, Akerley W, Schabel MC,
Hong DS
, Uehara C, Chhabra A, Warren T, Mather GG, Evans BA, Woodland DP, Swabb EA, Kurzrock R. Phase I clinical trial of MPC-6827 (Azixa), a microtubule destabilizing agent, in patients with advanced cancer. Mol Cancer